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Abstract 16 
This study provides an insight into the prevalence of (fluoro)quinolones (FQs) and their specific 17 
quinolone qnrS resistance gene in the aquatic environment from the Avon river catchment area 18 
receiving treated wastewater from 5 wastewater treatment plants (WWTPs), serving 1.5 million 19 
people and accounting for 75% of inhabitants living in the catchment area in the South West of 20 
England. FQs were analysed by stereoselective chiral chromatography and tandem mass spectrometry 21 
and their specific qnrS resistance gene was measured with digital PCR, which allowed for 22 
spatiotemporal evaluation of the prevalence of FQs and qnrS across the catchment. Ofloxacin, 23 
ciprofloxacin, nalidixic acid and norfloxacin were found to be ubiquitous with daily loads reaching a 24 
few hundred g/day in wastewater influent and tens of g/day in receiving waters. This was in contrast 25 
to other FQs analysed: flumequine, nadifloxacin, lomefloxacin, ulifloxacin, prulifloxacin, 26 
besifloxacin and moxifloxacin, which were hardly quantified. Enantiomeric profiling revealed that 27 
ofloxacin was enriched with the S-(-)-enantiomer, likely deriving from its prescription as the more 28 
potent enantiomerically pure levofloxacin, alongside racemic ofloxacin. While ofloxacin’s 29 
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enantiomeric fraction (EF) remained constant, high stereoselectivity was observed in the case of its 30 
metabolite ofloxacin-N-oxide. The removal efficiency of quinolones during wastewater treatment at 31 
5 WWTPs utilising either trickling filters (TF) or activated sludge (AS), was compound and 32 
wastewater treatment process dependent, with AS providing better efficiency than TF. The qnrS 33 
resistance gene was ubiquitous in wastewater. Its removal was WWTP treatment process dependent 34 
with TF performing best and resulting in significant removal of the gene (from 28 to 75%). AS 35 
underperformed with only 9% removal in the case of activated sludge and actual increase in the gene 36 
copy number within sequencing batch reactors (SBRs). Interestingly, the data suggests that higher 37 
removal of antibiotics could be linked with high prevalence of the gene (SBR and WWTP E) and vice 38 
versa  low removal of antibiotic is correlated with lower prevalence of the gene in wastewater effluent 39 
(TF, WWTP B and D). This is especially prominent in the case of ofloxacin and could indicate that 40 
AS might be facilitating antimicrobial resistance (AMR) prevalence to higher extent than TF. 41 
Wastewater-based epidemiology (WBE) was also applied to monitor any potential misuse (e.g. direct 42 
disposal) of FQs in the catchment. In most cases higher use of antibiotics with respect to official 43 
statistics (i.e. ciprofloxacin, ofloxacin) was observed, which suggests that FQs management practice 44 
require further attention.  45 
 46 
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1. Introduction 48 
Antimicrobial resistance (AMR) is considered to be one of the most significant threats worldwide. 49 
Defined as the ability of a population of microorganisms to neutralise the effect of an antimicrobial 50 
drug, AMR is a natural process that has been greatly accelerated by misuse of available 51 
antimicrobials. With limited innovation in drug discovery for new antibiotics, current strategies are 52 
directed to monitor the usage of antibiotics. A key factor that plays a fundamental role in AMR is 53 
microbial exposure to antibiotics (Rizzo et al. 2013). Indeed, such exposure at sub-lethal 54 
concentrations could lead to selective advantages for certain resistant strains, in particular those 55 
containing antibiotic resistant genes (ARGs), and enhance the possibilities of their survival, 56 
development and spread. A number of resistance mechanisms are acknowledged, such as mutation of 57 
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existing DNA, DNA exchange by vertical transmission or by horizontal gene transfer that can occur 58 
by (i) transformation, (ii) transduction and (iii) exchange of conjugative plasmids between bacteria 59 
that are physically connected. The latter mechanism is the most common in nature (Grohmann, Muth, 60 
and Espinosa 2003). 61 
Along with hospitals, well-known hotspots for the spread of AMR are wastewater treatment plants 62 
(WWTPs) (Rizzo et al. 2013). This results from the exposure of microbial communities living in the 63 
reservoir of the WWTP to sub-inhibitory concentrations of antibiotics contained in the sewage from 64 
households, pharmaceutical plants and hospitals. Therefore, the chances for a microorganism to gain 65 
such exposure and survive are likely to encourage horizontal gene transfer and the development of 66 
AMR. Some studies have reported evidence that these environmental hotspots coincide with an 67 
increased level of antibiotic resistance genes (ARGs), like in the case of waters receiving effluent 68 
from pharmaceutical plants. Others have found that biocides and metals are also fundamental AMR 69 
drivers (Singer et al. 2016). 70 
Antibiotics are often chiral molecules and, in such cases, are frequently marketed as racemates (as 71 
1:1 ratio of enantiomers in each enantiomeric pair) or as enantiomerically pure eutomers. Enantiomers 72 
of the same drug, despite having the same physicochemical properties, differ in the spatial 73 
arrangement of enantiomers, which results in diverse interactions not only at the molecular level, but 74 
also at the biological level, where differences in pharmacodynamic and pharmacokinetic responses 75 
could occur. The fact that enantiomers stereoselectively react with biological systems, that are chiral 76 
themselves (e.g. enzymes), is carefully monitored in pharmaceutical legislation and policy. 77 
Unfortunately, the awareness that such differing interactions could occur in the environment is 78 
limited. This is mainly due to lack of research and unavailability of analytical methods allowing for 79 
analysis at the enantiomeric level. Indeed, during its environmental life-cycle, a chiral antibiotic could 80 
alter its stereoisomeric composition during WWTP processes and in the environment. The impact of 81 
stereochemistry on the environmental fate and effects of several chiral contaminants is well 82 
demonstrated. Examples include illicit drugs, beta-blockers and antidepressants (Castrignano et al. 83 
2017, Evans, Bagnall, and Kasprzyk-Hordern 2017, Kasprzyk-Hordern and Baker 2012). It has been 84 
proven that stereoselective transformation together with enantiomer-dependent ecotoxicity frequently 85 
occur in the environment (Rice et al. 2018). Moreover, the formation of enantiomers not believed to 86 
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exist in nature, such as 1S,2R-(+)-ephedrine, was also reported during wastewater treatment 87 
(Kasprzyk-Hordern and Baker 2012). Despite these findings, there is a gap in the knowledge of the 88 
environmental fate of chiral antibiotics. A pioneering study highlighted alterations in the enantiomeric 89 
composition of ofloxacin in receiving waters after the wastewater effluent discharge point, enriched 90 
with S-(-)-enantiomer, with respect to the initial racemic composition in the upstream waters 91 
(Castrignano et al. 2018). Hence, such an effect could influence activity and toxicity of the chiral 92 
antibiotic in the environment. As a result, tackling issues of stereoisomerism of chiral antibiotics in 93 
the urban water cycle and in the surrounding environment is of utmost relevance as it could also affect 94 
the interactions with microbes living in the WWTP and receiving waters with possible effects on 95 
AMR evolution and spread.  96 
This paper aimed to: 97 
(i) verify occurrence and (stereoselective) bio-physicochemical transformation of FQs 98 
during wastewater treatment and in receiving waters; 99 
(ii) verify occurrence and fate of fluoroquinolone (FQN) resistance qnrS gene during 100 
wastewater treatment and in receiving water; 101 
(iii) estimate public exposure to FQs and qnrS using wastewater-based epidemiology 102 
(WBE).  103 
Quinolones were selected as the target compounds as they satisfy a number of criteria to first attempt 104 
the realisation of the above objectives: (i) they are extensively used globally in the treatment of a 105 
wide range of illness, including urinary tract, respiratory and gastrointestinal infections; (ii) previous 106 
studies have detected quinolones in urban wastewater with concentrations up to microgram per litre 107 
(Rizzo et al. 2013); (iii) due to their wide use, the quinolone resistance rate has increased since 1990s 108 
(Aldred, Kerns, and Osheroff 2014); (iv) the World Health Organization (WHO) has included them 109 
in the list of “Highest Priority Critically Important Antimicrobials“ for human medicine 110 
(Organization 2016); and (v) many quinolones exist as enantiomers.  111 
 112 
2. Experimental 113 
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2.1.Chemicals and materials 114 
The following quinolones were selected for the study: (a) chiral: (±)-ofloxacin, (±)-ofloxacin-N-115 
oxide, (±)-desmethyl-ofloxacin, (±)-lomefloxacin, (±)-moxifloxacin, S,S-moxifloxacin-N-sulfate, R-116 
(+)-besifloxacin, (±)-prulifloxacin, (±)-ulifloxacin, (±)-flumequine and (±)-nadifloxacin; (b) achiral: 117 
ciprofloxacin, desethylene-ciprofloxacin, norfloxacin and nalidixic acid. Their chemical structure, 118 
properties, chirality, marketing, use, metabolic and excretion patterns, and stereoselective metabolism 119 
are presented in Figure S1, Table S1-S2. 120 
The elution order of the following analytes was determined as reported in Castrignanò et al. 2018 by 121 
using stereoisomerically pure standard solutions: S-(-)-ofloxacin, also known as levofloxacin, R,R-122 
moxifloxacin, S,S-moxifloxacin and S,S-moxifloxacin-N-sulfate. The following deuterated and 123 
isotopic analogues of target analytes were used as isotopically-labelled internal standards: 124 
ciprofloxacin-D8, (±)-ofloxacin-D3, (±)-desmethyl-ofloxacin-D8 and (±)-flumequine-13C3. 125 
Standard stock solutions were prepared at 1 mg mL-1 in methanol for all the analytes, with exception 126 
of (±)-prulifloxacin, (±)-ulifloxacin, (±)-ofloxacin-D3 and (±)-flumequine-13C3 that were dissolved in 127 
acetonitrile, and (±)-lomefloxacin, desethylene-ciprofloxacin, ciprofloxacin-D8 and (±)-desmethyl-128 
ofloxacin-D8 that were dissolved in water. Mixed working solutions containing all analytes were 129 
prepared from stock solutions by dilution with mobile phase. They were used for the preparation of 130 
the aqueous standard calibration solutions and for spiking samples. Stock and working solutions of 131 
standards were stored at -20° C.  132 
HPLC-grade methanol, acetonitrile, ammonium formate and formic acid (≥96%) were purchased 133 
from Sigma Aldrich (UK). Ultrapure water was obtained from a MilliQ system, UK. All glassware 134 
was deactivated in order to prevent the adsorption of polar compounds to the hydroxyl sites on the 135 
glass surface. The deactivation process consisted of rinsing cycles with 5% dimethyldichlorosilane in 136 
toluene once, with toluene twice and with methanol thrice. 137 
2.2.The study area and sampling points 138 
Wastewater influent and effluent were collected for 7 consecutive days running from Wednesday to 139 
Tuesday between June and October 2015 from five major WWTPs (Figure 1, Table 1, sites A-E) 140 
contributing to one river catchment in the South-West UK and covering an area of approximately 141 
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2,000 km2 and the population of ~1.5 million (this constitutes >75% of the overall population in the 142 
catchment). All WWTPs use conventional sedimentation following secondary treatment (except for 143 
sequencing batch reactors (SBRs) that used decantation following settling in-situ). Respective 144 
wastewater and river water samples were collected on the same days. Selected WWTPs utilise 145 
different treatment technologies: activated sludge (AS) and trickling filters (TF). Influent wastewater 146 
samples were collected between screening and primary sedimentation. Digested sludge was also 147 
collected at WWTP B and E over three consecutive days. River water was collected from upstream 148 
and downstream of the effluent discharge point at varying distances depending on accessibility (Table 149 
1).  River water was not collected for Site E as the WWTP discharges directly to the estuary.       150 
Influent wastewater was collected as volume proportional 24 h composites with average sub-sample 151 
collection frequencies of approximately 15 minutes using an ISCO 3700 autosampler. Sub-samples 152 
(80 mL) were cooled to 4˚C (samplers were packed with ice) during collection to limit biological 153 
activity and pooled after 24 h (Petrie et al., 2017).  This sampling mode should provide unbiased 154 
sampling error distributions and be ≤20 % for quinolones with ≥50 ‘pulses’ (p, number of toilet 155 
flushes containing the micropollutant of interest) per day. Effluent wastewater samples were collected 156 
using time proportional approach due to the limited variation of this matrix over 15-minute intervals 157 
as discussed elsewhere (Petrie et al. 2016). River waters (8 L) were collected as grab samples.  All 158 
samples were transported to the laboratory on ice for further processing.  It is important to mention 159 
here that one-week monitoring study did not account for several variables including seasonality, 160 
including rainfall, sunlight, microbial activity, season dependent pharmaceutical prescription. 161 
2.3.Sample preparation and analysis 162 
2.3.1. Antibiotic analysis using chiral liquid chromatography coupled with tandem mass 163 
spectrometry 164 
Once in the laboratory, wastewater samples were filtered through GF/F 0.7 µm glass fibre filter 165 
(Whatman, UK) and 50 mL of filtered wastewater was spiked with 50 µL of a mixture of isotopically-166 
labelled internal standards at 1 mg L-1. Analytes were extracted using SPE and Oasis HLB cartridges 167 
(60 mg, Waters, UK), previously conditioned with 3 mL of methanol and equilibrated with 3 mL of 168 
ultrapure water. 50 mL of spiked environmental samples were loaded on HLB cartridges that were 169 
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then washed with 1 mL of ultrapure water. The elution was carried out with 4 mL of methanol into 5 170 
mL silanised glass tubes. The extracts were transferred to the TurboVap evaporator (Caliper, UK) 171 
and completely evaporated to dryness under nitrogen flow (5-10 psi). Samples were reconstituted 172 
with 0.5 mL of 10 mM ammonium formate/methanol 1:99 v/v with 0.05% formic acid and filtered 173 
through 0.2 µm PTFE filters. The filtered samples were transferred to polypropylene plastic vials 174 
bonded pre-slit PTFE/Silicone septa (Waters, UK) and then 20 µL were directly injected into a chiral 175 
HPLC-MS/MS system. Samples were prepared and analysed in duplicate. 176 
Wastewater suspended particulate matter (SPM) was filtered from the wastewater samples using 177 
GF/F 0.7 µm glass fibre filters. The SPM collected was frozen, before being freeze-dried, 178 
homogenised, weighed to 0.25 g and spiked with 50 µL of a mixture of isotopically-labelled internal 179 
standards at 1 mg L-1. Microwave assisted extraction was carried out with 30 mL of 50:50 methanol: 180 
acidified ultrapure water (pH 2) at 110 °C for 30 minutes using 800 W MARS 6 microwave (CEM, 181 
UK). Samples were then filtered with GF/F 0.7 µm glass fibre filters and diluted with acidified 182 
ultrapure water (pH 2) to < 5% methanol. SPE was then carried out on the filtrate using Oasis MCX 183 
(60mg, Waters, UK). The cartridges were conditioned with 2 mL methanol and equilibrated with 2 184 
mL acidified ultrapure water (pH 2). The entire filtrate (300 mL) was loaded onto the cartridge and 185 
then cartridge then dried under vacuum. The samples were then eluted in two fractions. An acidic 186 
fraction with 2 mL acidified methanol (2 mL 0.6% formic acid in methanol) and a basic fraction with 187 
3 mL 7% ammonium hydroxide in methanol. These were evaporated to dryness with TurboVap 188 
evaporator at 40°C under nitrogen and then reconstituted with 0.5 mL 80:20 ultrapure water:methanol 189 
and filtered 0.2 µm PTFE filters. The filtered samples were transferred to polypropylene plastic vials 190 
bonded pre-slit PTFE/Silicone septa and then 20 µL were directly injected into a chiral HPLC-191 
MS/MS system. Samples were prepared and analysed in duplicate. This was the same procedure used 192 
in the preparation of digested solids. Quantity of SPM per litre of wastewater was carried out by 193 
filtering 100 mL of wastewater through a pre-weighed GF/F 0.7 µm glass fibre filter, this was then 194 
dried and reweighed.  195 
Samples were analysed using a Waters ACQUITY UPLC® system (Waters, Manchester, UK). 196 
Chromatographic separation of all the analytes was carried out using a chiral CHIRALCEL® OZ-RH 197 
column (5 μm particle size, L × I.D. 15 cm × 2.1 mm, Chiral Technologies, France) with a 2.0 mm × 198 
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2.0 mm guard filter (Chiral Technologies, France). The column temperature was set at 30°C. The 199 
autosampler was kept at 4°C. A mobile phase consisting of 10 mM ammonium formate/methanol 200 
1:99 v/v with 0.05% formic acid was used at a flow rate of 0.1 mL min-1 under isocratic conditions. 201 
The MS system was a triple quadrupole mass spectrometer (Xevo TQD, Waters, Manchester, UK) 202 
equipped with an electrospray ionisation source. Analyses were performed in positive mode with an 203 
optimised capillary voltage of 3 kV, source temperature of 350°C, desolvation temperature of 350°C 204 
and desolvation gas flow of 650 l h-1. Nitrogen, supplied by a high purity nitrogen generator (Peak 205 
Scientific, UK), was used as a nebulising and desolvation gas. Argon (99.999%) was used as a 206 
collision gas. MassLynx 4.1 (Waters, UK) was used to control the Waters ACQUITY system and the 207 
Xevo TQD. Data processing was carried out on TargetLynx software (Waters, Manchester, UK). 208 
The mass spectrometer acquired data using MRM mode. Two MRM transitions were selected for 209 
each compound. The most abundant transition product ion was typically used for quantification, 210 
whilst the second ion was used for confirmation purposes. The MRM transitions, CV and CE values 211 
of the studied compounds are presented in Table S3. The method was fully validated as described 212 
elsewhere (Castrignano et al. 2018) and (Proctor et al. 2019) (Figure S2, Table S4-S7). 213 
2.3.2. qnrS gene quantification using dPCR 214 
2.3.2.1. DNA extraction and quantification 215 
1 mL of unfiltered wastewater samples were centrifuged in sterilised micro-centrifuge tubes for 5 216 
minutes at 3000 g. The supernatant was discarded and the remaining cell pellet was re-suspended in 217 
200 μL phosphate buffered saline (PBS). 5 μL lysozyme were then added, followed by an incubation 218 
at 37 °C for 15 minutes. 200 μL of binding buffer and 40 μL proteinase K were added and incubated 219 
at 70 °C for 10 minutes. DNA extraction was performed in accordance with manufacturer’s 220 
instructions (High Pure PCR Template Preparation Kit, Roche, Germany). Briefly, 100 μL of 221 
isopropanol alcohol was added. The samples were then transferred to a filter tube assembled inside a 222 
collecting tube and centrifuged for a minute at 8000 g. The supernatant was discarded and the filter 223 
tube assembled in a new collecting tube. 500 μL of inhibitor buffer and 500 μL of washing buffer 224 
were respectively added after cycles of centrifugation at 8000 g. The supernatant was finally 225 
discarded before centrifugation for 10 min at 9000 g. The filter tube was then assembled into a 226 
9 
 
sterilised micro-centrifuge tube. 200 μL of elution buffer pre-warmed to 60 ᵒC were used. Samples 227 
were centrifuged at 8000 g for a minute. The resulting DNA samples in the micro-centrifuge tubes 228 
were stored at -20 °C. To determine the success of the DNA extraction method, DNA was quantified 229 
by using a Thermofisher Nanodrop instrument, that was first calibrated and blanked using pure water.  230 
2.3.2.2. qnrS gene quantification using dPCR 231 
A QuantStudio 3D Digital PCR system was used with a QuantStudio 3D PCR V2 kit (Life 232 
Technologies, Thermo Fisher Scientific). PCR reaction mixtures were prepared with 7.3 μL Master 233 
Mix V2, 0.7 μL qnrS TaqMan Assay (20 X primer/ probe mix), 1.5 μL nuclease free water and 6.0 234 
μl DNA sample. 14.5 μL of this mixture were loaded onto the digital PCR load blades and distributed 235 
in high density nanofluidic PCR chips that were loaded onto a GeneAmp PCR 9700 system. 236 
The program was run using thermal cycling conditions. Temperature was first ramped to 95 °C and 237 
held for 10 min. It was then lowered to 60 °C for 2 min before increasing to 98 °C for 30 seconds. 238 
This cycle between 60 °C and 98 °C was repeated 40 times to allow for efficient gene amplification. 239 
The system was then lowered being to 60 °C and held for 2 min, before cooling to room temperature. 240 
After cooling, each chip was processed using the QuantStudio 3D Digital PCR system. 241 
AnalysisSuiteTM software was used to get quantification of the targeted gene and statistical analysis 242 
of the results. 243 
2.4.Calculations 244 
In order to obtain daily mass loads, the concentrations of analytes expressed in ng L-1 (Tables S8-245 
S12) were multiplied by the flow rate (L day-1) and then normalised by the population size of the 246 
catchment area. FQs’ and qnrS gene removal during wastewater treatment, expressed as a percentage, 247 
was calculated by considering hydraulic retention time and the difference between the influent load 248 
and the effluent load in relation to the influent load. 249 
Results from digital PCR analysis were given as copies μL-1 (Table S13). In order to obtain daily copy 250 
loads, qnrS copies expressed in copies day-1 were multiplied by the flow rate (L day-1) and then 251 
normalised by the population size of the catchment area. 252 
Concentrations of the analytes in SPM from influent wastewater during the monitoring week are 253 




3. Results and Discussion 256 
3.1. FQs during wastewater treatment: activated sludge vs trickling filters technology 257 
3.1.1. Occurrence of FQs in wastewater 258 
Ofloxacin and its metabolites. In the investigated catchment area, the highest loads among chiral 259 
quinolones were found for ofloxacin in influent wastewater from WWTP E. Indeed, the total average 260 
load was found at 53±14 g day-1, ten times higher than in other WWTPs (Figure 2). To assess whether 261 
stereoselective enrichment or depletion of the enantiomeric composition of the drug occurred, the 262 
enantiomeric fraction (EF) was used as a dimensionless indicator of (i) the equal amount of two 263 
enantiomers in the case of EF = 0.5 or (ii) the predominance of one enantiomer with respect to the 264 
other in the case of EF <0.5 (predominance of S-(-)-ofloxacin) or >0.5 (predominance of R-(+)-265 
enantiomer) (Figure 2). EFofloxacin was found with an average value of 0.13±0.07 in influent samples 266 
from WWTP A, 0.26±0.03 in WWTP E, 0.28±0.05 in WWTP C, 0.36±0.02 in WWTP D and 267 
0.40±0.03 in WWTP B. This signifies that a high proportion of ofloxacin was present as the S-(-)-268 
enantiomer, likely deriving from the prescription of enantiomerically pure isomer, levofloxacin, that 269 
is more potent than R-(+)-ofloxacin (Al-Omar 2009). Average effluent loads were found to be 270 
considerably lower than influent in the majority of the sites with expected high levels observed at 271 
21±4 g day-1 for WWTP E. No significant change in EF was observed across all WWTPs (EFWWTP A, 272 
E unvaried, EFWWTP B 0.32±0.03, EFWWTP C 0.32±0.04 and EFWWTP D 0.34±0.01), signifying that the 273 
wastewater treatment process had no impact in altering the enantiomeric composition.  274 
The presence of ofloxacin metabolites had a more scattered profile in the studied WWTPs (Figures 275 
3, 5). Ofloxacin-N-oxide was present at an average load of 0.2 and 3.8 g day-1 in influent wastewater 276 
from WWTP A and E, most likely due to human metabolism (Figure 4). This was confirmed by WBE 277 
estimated ofloxacin-N-oxide load (0.2 – 4.0 g day-1) based on measured daily loads of ofloxacin in 278 
wastewater (Table 2). In effluent, ofloxacin-N-oxide was found at quantifiable average load of 0.9 g 279 
day-1 only in WWTP E (Figure 4). In WWTP B, C and D ofloxacin-N-oxide was present in both 280 
matrices but still below the method limit of quantification (MQL), whilst it was not detected in 281 
effluent samples from WWTP A. The enantiomeric composition favoured the S-(-)-enantiomer in 282 
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influent wastewater at WWTP A (EF=0) and WWTP E (EF=0.22). It is important to highlight that 283 
EFofloxacin-N-oxide from effluent WWTP E was 0.45±0.03, showing that the enantiomeric composition 284 
was likely altered during the wastewater treatment process. S-(-)-Desmethyl-ofloxacin was detected 285 
but was not quantifiable in all influent and effluent samples from WWTP A. R-(+)-desmethyl-286 
ofloxacin was at <MQL in a couple of influent and effluent samples (Figure 3). In WWTP B 287 
desmethyl-ofloxacin was found at 0.33 g day-1 only in one influent sample with a slight predominance 288 
of the S-(-)-enantiomer. In WWTP C, S-(-)-desmethyl-ofloxacin reached the average load of 0.7 g 289 
day-1 in influent and 0.4 g day-1 in effluent, whilst R-(+)-desmethyl-ofloxacin was <MQL. In WWTP 290 
D, S-(-)-desmethyl-ofloxacin reached the average load of 0.1 g day-1 in influent and 0.05 g day-1 in 291 
effluent, whilst R-(+)-desmethyl-ofloxacin was found at 0.03 g day-1 in influent and in the same 292 
amount from one day in effluent wastewater. In WWTP E, desmethyl-ofloxacin was not detected in 293 
any analysed samples.     294 
Interestingly, the analysis of the SPM from all the sites indicated ofloxacin’s partitioning to solids 295 
with higher levels recorded for the S-(-)-enantiomer (Figure 5). Ofloxacin’s metabolites were not 296 
detected in SPM due to their high polarity. 297 
Ciprofloxacin and its metabolites. Ciprofloxacin, a non-chiral fluoroquinolone, was detected in all 298 
collected samples (Figure 2). Its metabolite, desethylene-ciprofloxacin, was also present in most 299 
analysed samples. The average influent concentration of ciprofloxacin was 427±86 ng L-1 that 300 
corresponded to a load of 65±8 g day-1. There was a significant decrease in load from influent to 301 
effluent (i.e. average effluent load was 22±3 g day-1) (Figure 2). Wastewater influent derived SPM 302 
average daily loads were much lower and spanned from 0.01 (WWTP B) to 0.3 (WWTP D) g day-1 303 
(Figure 5).  304 
Nalidixic acid. The highest loads of nalidixic acid were recorded in WWTP E (4.9±1.3 g day-1) 305 
followed by WWTP C (0.8±0.0 g day-1) and then WWTP B, A, D with loads 0.09, 0.07 and 0.01 g 306 
day-1 respectively. The removal efficiency of nalidixic acid was site dependent and spanned between 307 
38 to 82%. Due to varying removal of nalidixic acid from wastewater, effluent loads varied from 308 
1.8±0.5 g day-1 at WWTP D, 2.4±0.5 g day-1 at WWTPC and 3.1±0.2 g day-1 at WWTP A and reached 309 
the highest levels at WWTP E 12.6±5.1 g day-1 (Figure. 2). Nalidixic acid was quantified in influent 310 
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wastewater SPM from WWTP A and E only and spanned from 0.001 to 0.1 g day-1 in WWTP A and 311 
E respectively (Figure 5). 312 
Norfloxacin. Norfloxacin was quantified in wastewater influent at three sites only: WWTP D, B and 313 
E with average daily loads spanning from 0.6±0.4 g day-1 at WWTP D, through 1.4±0.4 g day-1 at 314 
WWTP B to 98.4±60 g day-1 at WWTP E. WWTP removal was in the range 19% (WWTP E) to 75% 315 
(WWTP C), which lead to daily loads in effluent denoting 0.4±0.1 g day-1 at WWTP D, 0.9±0.3 g 316 
day-1 at WWTP B to 29±5.3 g day-1 at WWTP E (Figure 2). Norfloxacin was quantified in influent 317 
wastewater SPM from WWTP B only with daily loads at 0.11±0.05 g day-1 (Figure 5). 318 
Flumequine. (±)-Flumequine was found in all sites, interestingly, with a different enantiomeric 319 
signature for each site. In WWTP A and B, the E1-enantiomer was at <MQL in influent (liquid phase), 320 
but quantifiable in effluent samples with a load average of 0.1 g day-1 for both sites. E2-enantiomer 321 
was barely detected in both matrices. In WWTP C E1-enantiomer was detected in influent and 322 
quantified more frequently than E2 with a load average of 0.3 g day-1. Both enantiomers were at 323 
<MQL in all effluent samples. In WWTP D, E1-enantiomer was quantified in all influent and effluent 324 
wastewater samples with an average load of 0.03 g day-1, while E2 was mostly <MQL. Hence, EF 325 
could not be calculated. In WWTP E, E1-enantiomer was quantified only in two influent samples, 326 
and it was present at an average load of 1.1 g day -1 in effluent samples, while E2 was not found in 327 
any of the two matrices (Tabs S10-14).  328 
Interestingly, flumequine was the most prevalent FQN in SPM derived from influent wastewater. 329 
This is likely due to its relatively high hydrophobicity (Table S2). Flumequine was quantified at 330 
average daily loads of 7 g day-1. Average EF across four WWTPs denoted 0.8 indicating a significant 331 
enrichment of flumequine with E1 enantiomer, likely due to stereoselective human metabolism as 332 
flumequine is marketed as a racemate. (Figure 5). 333 
Other FQs. S,S-Moxifloxacin and moxifloxacin-N-sulfate were detected only in WWTP D in a few 334 
samples from influent and effluent. (±)-Nadifloxacin was found at <MQL only in influent samples 335 
from WWTP B. In WWTP C, the first-eluting enantiomer was detected more frequently than the 336 
second one in influent samples, whilst it was more consistently detected in effluent samples. An 337 
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analogue profile was seen in WWTP E. (±)-Lomefloxacin was only found in WWTP C at quantifiable 338 
amounts in three effluent samples, whilst it was not detected in influent samples (Tables S10-14). (±)-339 
Prulifloxacin, (±)-ulifloxacin and R-(+)-besifloxacin have not been detected in the catchment area 340 
investigated.  341 
3.1.2. Fate of FQs during wastewater treatment 342 
The following WWTP treatment technologies are used in studied WWTPs: TF (WWTP B, C and D) 343 
or AS (WWTP A), and SBR (WWTP E) (Table 1). The sewer residence time along with features of 344 
the treatment process, such as solid retention time and hydraulic retention time, are also included in 345 
Table 1. Hydraulic retention time varied from 11h (WWTP E) to 46h (WWTP A) and solid retention 346 
time was from 4h (WWTP E) to 19h (WWTP A). These two parameters are widely regarded as being 347 
of primary importance for the FQs removal (Batt, Kim, and Aga 2007, Gao et al. 2012, Li et al. 2013). 348 
Figure 6 summarises the removal efficiency of target quinolones in this study. The sorption on AS is 349 
the main mechanism involved in the removal process of FQs from wastewater (Conkle et al. 2010, 350 
Golet et al. 2003, Jia et al. 2012) followed by biodegradation, whose roles in the prevalence and 351 
dissemination of AMR are not yet fully understood (Van Doorslaer et al. 2014). Sorption is more 352 
highly influenced and driven by electrostatic interactions rather than hydrophobic partitioning (Golet 353 
et al. 2003, Lindberg et al. 2006, Tolls and technology 2001). Due to the amphoterism of FQs such 354 
as (±)-ofloxacin, norfloxacin and (±)-moxifloxacin, partitioning is also pH-dependent (Langlois et al. 355 
2005, Takács-Novák et al. 1992, Van Doorslaer et al. 2014, Kümmerer 2008) and influenced by the 356 
salinity of the water phase (Van Doorslaer et al. 2014). The results of this study indicate that the 357 
removal efficiency of FQs is compound and wastewater treatment process dependent (Figure 6). 358 
Ciprofloxacin showed the highest removal efficiency during trickling filters treatment (38-73% in 359 
WWTPs B-D vs 15-64% in WWTPs A and E), while ofloxacin showed the highest removal during 360 
AS treatment treatment (22-62% in WWTPs B-D vs 57-75% in WWTPs A and E). Nalidixic acid and 361 
norfloxacin showed better removal during AS than TF treatment. No clear stereoselectivity was 362 
observed in the case of chiral ofloxacin. 363 
3.1.3. Occurrence of qnrS gene during wastewater treatment 364 
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As highlighted by Van Doorslaer et al. (2014), FQs can induce the AMR phenomenon in microbial 365 
communities present in the environment, as these drugs are excreted unchanged (up to 70%) with 366 
only a small proportion being metabolised. Three mechanisms for the development of resistance have 367 
been described in literature. These are caused by mutations leading to (i) target-site alterations and 368 
(ii) decreased drug accumulations due to a change in the membrane permeability, and (iii) by 369 
horizontal gene transfer carrying qnr gene, like in the case of plasmids, that are mobile quinolone 370 
resistance elements (Ruiz 2003, Jacoby 2005). The latter mechanism of resistance to FQs results from 371 
the binding between the qnr protein and the target topoisomerase, that avoids the action of the 372 
antibiotic on the targeted enzyme (Redgrave et al. 2014). Examples of plasmid mediated quinolone 373 
resistance genes are from (i) the families of qnr genes (qnrB, qnrS, etc.), (ii) a variant of an 374 
aminoglycoside acetyl transferase, aac(6)-Ib-cr and (iii) the efflux systems that can remove the drug 375 
through the usage of transporters (i.e. oqxAB and qepA) (Redgrave et al. 2014). In this study, the 376 
targeted resistance gene was qnrS because of (i) its reduced susceptibility to fluoroquinolones as 377 
stated elsewhere (Rodriguez-Mozaz et al. 2015) (Marti, Variatza, and Balcázar 2014) and (ii) its 378 
prevalence in environmental matrices as reported in previous studies (Castrignano et al. 2018, Marti 379 
et al. 2016).  380 
In this study, in order to verify whether the level of resistance gene detected in the different areas of 381 
the catchment corresponds with estimated quinolone loads, the qnrS gene extracted from the DNA 382 
contained in the wastewater samples was quantified through the use of digital PCR (Table S13). 383 
Figure 7 shows the concentration of the gene qnrS in influent and effluent wastewater collected at 384 
sites A-E during one monitoring week. The results confirm previous published findings indicating 385 
that resistant genes are present in wastewater (Marti et al. 2016). Overall, a higher absolute copy 386 
number of qnrS gene was observed in this study with respect to findings in Rodriguez-Mozaz et al. 387 
(Rodriguez-Mozaz et al. 2015). Interestingly, the fate of the qnrS gene was different in different 388 
WWTPs, with TFs (WWTP B, C and D) performing best and resulting in significant removal of the 389 
gene (from 28 to 75%). AS and SBRs underperformed with only 9% removal of qnrS gene in the case 390 
of AS and actual increase of the number of copies of the gene during SBR. 391 
 Interestingly, the data suggests that higher removal of antibiotic is linked with low removal of the 392 
gene (SBR and WWTP E) and vice versa, low removal of antibiotic is correlated with lower 393 
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prevalence of the gene in wastewater effluent (TF, WWTP B and D). This is especially prominent in 394 
the case of ofloxacin and could indicate that AS might be facilitating AMR prevalence to higher 395 
extent than TF.  396 
3.2.The catchment perspective 397 
The potential contamination of receiving waters by antibiotics and ARGs is highly influenced by a 398 
number of variables dependent on (i) the nature and the physico-chemical properties of the 399 
compounds, (ii) the environmental conditions such as the temperature and the effect of sunlight and 400 
(iii) the loads of pharmaceuticals, and therefore their dilution due to rainfall, discharge by WWTPs 401 
and the technology of treatment used for their removal (Baker and Kasprzyk-Hordern 2013). In this 402 
study a clear trend of increasing antibiotic concentration levels (and corresponding antibiotic loads) 403 
was observed with an increase of treated communal wastewater discharge, especially for samples 404 
collected downstream from wastewater discharge points (Figure 8). Interestingly, the qnrS gene was 405 
not quantifiable in receiving water samples with the method used. There are several possible reasons 406 
including analytical constraints as well dilution of wastewater effluent with receiving waters. 407 
As discussed in section 3.1, qnrS gene concentration levels remained fairly constant in all WWTPs. 408 
Quinolone concentrations varied across WWTPs (i.e. the highest total concentration levels were 409 
observed at WWTP E and the lowest in WWTP B (Figure 7)) but no clear pattern was observed when 410 
comparing antibiotic and gene concentration levels. However, normalisation of data to account for 411 
water flows revealed a strong correlation between daily loads of antibiotics present in each WWTP 412 
and corresponding loads of resistance genes. The highest loads of both FQs and ARG were observed 413 
in wastewater influent from site E followed by C, A, B, and D. Interestingly, this coincides with the 414 
size of a population served by individual WWTPs. It is therefore evident that the higher the 415 
population, the larger the load of both FQs and ARGs. The efficiency of wastewater treatment is 416 
another key variable influencing environmental FQs and ARG loads. Our study has shown that TF 417 
although are not as effective in the removal of FQs, they do remove ARGs. In contrast, AS process 418 
(also in SBR configuration) effectively removes FQs but also contributes to higher levels of ARGs.  419 
3.3.Wastewater based epidemiology 420 
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WBE was applied to estimate usage of antibiotics across the catchment. Antibiotic usage data 421 
obtained via wastewater analysis were then analysed against prescription data to highlight any misuse 422 
of quinolones. We have also applied this approach in a European study (Castrignanò et al. 2020) 423 
where spatiotemporal changes in quinolone usage across different European cities were observed.  424 
This study covers 75% of the population (~1.5 million people) residing in five urban areas (cities A-425 
E) served by the selected five major WWTPs which allows for comprehensive understanding of the 426 
quinolones usage in the study area (Table 2). Where possible, metabolites were considered as 427 
biomarkers of antibiotic consumption.  428 
Ofloxacin. Indeed, (±)-ofloxacin is mostly excreted unchanged in urine (90%), but it also undergoes 429 
metabolism in humans to form (±)-ofloxacin-N-oxide and (±)-desmethyl-ofloxacin. Therefore, these 430 
two metabolites were selected, alongside (±)-ofloxacin, as biomarkers. This is despite their low 431 
excretion rate, i.e. 1-5% as ofloxacin-N-oxide and 3-6% as desmethyl-ofloxacin. Ofloxacin is a chiral 432 
fluoroquinolone in which the S-(-)-enantiomer is significantly more potent as an antibiotic. In 2015, 433 
212 kg of (±)-ofloxacin and 120 kg of S-(-)-ofloxacin were prescribed in England according to PCA 434 
data (http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx). Taking into account the urinary 435 
excretion, the annual excreted amounts of R-(+)-ofloxacin and S-(-)-ofloxacin were calculated as 87.5 436 
kg and 186.5 kg, respectively. In particular, the latter calculation considered the excreted contribution 437 
from the racemate formulation (i.e. 87.5 kg) and the one from the pure S-(-)-drug (i.e. 99 kg). Hence, 438 
the consumption estimates from PCA data were 4 mg day-1 1000 people-1 as R-(+)-ofloxacin and 8 439 
mg day-1 1000 people-1 as S-(-)-ofloxacin. The estimates from wastewater analysis were fully in 440 
agreement with the NHS data only in city D served by WWTP D (5 mg day-1 1000 people-1 as R-(+)-441 
ofloxacin and 8 mg day-1 1000 people-1 as S-(-)-ofloxacin). Estimates were lower in the case of city 442 
B (WWTP B) with 2 mg day-1 1000 people-1 as R-(+)-ofloxacin and 3 mg day-1 1000 people-1 as S-(-443 
)-ofloxacin, whilst they were much higher in city E (WWTP E) (18 mg day-1 1000 people-1 as R-(+)-444 
ofloxacin and 51 mg day-1 1000 people-1 as S-(-)-ofloxacin). In the cities served by WWTPs A and C 445 
the estimates showed that S-(-)-ofloxacin usage was much higher (i.e. 42 and 24 mg day-1 1000 446 
people-1, respectively) than the R-(+)-ofloxacin (i.e. 6 and 10 mg day-1 1000 people-1 as R-(+)-447 
ofloxacin). The analysis of the data indicates that the ratio of the two enantiomers (R:S) is 1:2 in most 448 
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sites investigated, which indicates similar prescription habits. Only one site, city C (WWTP C), 449 
revealed the dominance of the S-(-)-enantiomer, which demonstrates that the enantiopure formulation 450 
(levofloxacin) was used and it was seven times higher when compared to other sites. With regard to 451 
the metabolic pattern, 2 and 4 kg were respectively excreted as R-(+)- and S-(-)-form of the 452 
metabolites. The official national estimates were in agreement with estimates from ofloxacin-N-oxide 453 
as drug target residue (DTR) for the site served by WWTP B and slightly lower for WWTPs C and 454 
D. The estimates were higher for WWTP E (i.e. 43 mg day-1 1000 people-1 as R-(+)-ofloxacin and 455 
177 mg day-1 1000 people-1 as S-(-)-ofloxacin) and WWTP A (91 mg day-1 1000 people-1 as S-(-)-456 
ofloxacin). The estimates from desmethyl-ofloxacin used as DTR were above in four sites over five 457 
(with exception for WWTP E, in which there was no detection of the metabolite). It could be 458 
concluded from the metabolic profiling data, that levofloxacin was highly consumed with respect to 459 
national prescription data and that the estimation of ofloxacin usage with WBE benefits from the 460 
metabolite estimates when they are both used as ofloxacin DTRs. 461 
Ciprofloxacin. As previously mentioned, ciprofloxacin was found at the highest loads in wastewater. 462 
The biomarkers used were ciprofloxacin itself and its metabolite desethylene-ciprofloxacin. In 2015, 463 
5782 kg of ciprofloxacin were prescribed in England according to PCA 464 
(http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx). As a result of human metabolism, 465 
ciprofloxacin is excreted as unchanged (40-50%) and as desethylene-ciprofloxacin (2-3%). 466 
Therefore, 2602 kg of ciprofloxacin and 116 kg of desethylene-ciprofloxacin were calculated as 467 
excreted quantities. Hence, ciprofloxacin consumption was estimated at 115 mg day-1 1000 people-1. 468 
The estimates calculated from wastewater analysis were below this estimate only in city B served by 469 
WWTP B (77 mg day-1 1000 people-1) and were much higher in cities D and E: 160 mg day-1 1000 470 
people-1 in city E (WWTP E), 256 mg day-1 1000 people-1 in city D (WWTP D), using ciprofloxacin 471 
as DTR. By using desethylene-ciprofloxacin, data were in agreement with consumption of 472 
ciprofloxacin (Table S19). Therefore, as estimates from wastewater data were higher than those from 473 
official prescription sources, veterinary usage needed to be accounted for as another source of 474 
ciprofloxacin. Indeed, enrofloxacin, a veterinary synthetic fluoroquinolone, is metabolised to 475 
ciprofloxacin and therefore it could considerably enhance ciprofloxacin levels in the environment. 476 
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Ciprofloxacin in conjunction with desethylene-ciprofloxacin were therefore considered suitable for 477 
biomarkers of ciprofloxacin use.  478 
Other FQs. WBE highlighted spatial differences in (i) norfloxacin and (ii) moxifloxacin uses in the 479 
same catchment area. 480 
 Norfloxacin is a FQ that was selected as a biomarker for its usage. 25-40% of its dose is excreted in 481 
urine and 5-10% as several metabolites within 24-48 hours, whilst 30% is excreted in faeces within 482 
48 hours. 1.1 kg of norfloxacin were prescribed in England in 2015 and national consumption was 483 
estimated in the range of 0.1 mg day-1 1000 people-1. The estimates from wastewater analysis were 484 
much higher in cities B, D and E and denoted: 61, 101 and 172 mg day-1 1000 people-1 respectively, 485 
whilst in cities A, C norfloxacin was not detected at all.  486 
The biomarkers chosen for moxifloxacin were the parent compound (S,S-moxifloxacin) and its sulfate 487 
metabolite. R,R-moxifloxacin is not prescribed and was monitored in order to ensure that no chiral 488 
inversion occurs in the environment, therefore it was not used for WBE calculations. From PCA, 39.6 489 
kg were prescribed and the relative consumption was estimated at 3 mg day-1 1000 people-1, by 490 
considering excretion of 20% and 25% as unchanged in urine and in faeces respectively and 35% as 491 
sulfate in faeces. Similar estimates from wastewater analysis were 16 and 17 mg day-1 1000 people-1 492 
in two sites only corresponding to WWTPs D and E, respectively.   493 
An overall agreement of estimates between official PCA data and wastewater analysis was observed 494 
in the case of nalidixic acid consumption. The parent compound was used as DTR. This choice was 495 
also supported by the hypothesis that in wastewater faecal bacteria might hydrolyse the glucuronide 496 
conjugates highly formed during the metabolism and thus release the nalidixic acid. Its metabolism 497 
produces also glucuronides of 7-hydroxynalidixic acid (2-3% as unchanged), but they were not taken 498 
into account in this study. National official consumption estimates for nalidixic acid were 0.3 mg day-499 
1 1000 people-1. In the majority of the sites similar estimates were calculated (average load of 3 mg 500 
day-1 1000 people-1) with exception for the site served by WWTP E (average load of 14 mg day-1 501 
1000 people-1).  502 
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The prodrug (±)-prulifloxacin was not prescribed according to PCA data and, as confirmed by 503 
wastewater analysis, neither (±)-prulifloxacin nor its active compound ulifloxacin were detected in 504 
the wastewater samples. (±)-Lomefloxacin was also not prescribed and data from wastewater analysis 505 
were overall in agreement in all the sites (in WWTP B it was detected <MQL only in one day, 506 
therefore estimates were not considered).  507 
4. Conclusions 508 
This study focussed on understanding stereoselective spatiotemporal speciation of FQs and the 509 
corresponding quinolone qnrS resistance gene in a river catchment in SW England. The conclusions 510 
are as follows: 511 
1. Ofloxacin, ciprofloxacin, nalidixic acid and norfloxacin were ubiquitous in the studied 512 
catchment with daily loads in the river reaching tens of g day-1 in receiving water and a few 513 
hundred g day-1 in wastewater influent. This is in contrast to other FQs studied, which were 514 
undetected: flumequine, nadifloxacin, lomefloxacin, ulifloxacin, prulifloxacin, besifloxacin 515 
and moxifloxacin. 516 
2.  Ofloxacin was present in the catchment as the S-(-)-enantiomer, likely deriving from the 517 
prescription of enantiomerically pure and much more potent levofloxacin, alongside racemic 518 
ofloxacin. While EFofloxacin remained constant, high stereoselectivity was observed for its 519 
metabolite ofloxacin-N-oxide.  520 
3. The removal efficiency of quinolones during wastewater treatment is compound and 521 
wastewater treatment process dependent. Ciprofloxacin showed the highest removal 522 
efficiency during TF treatment, while ofloxacin showed the highest removal during AS 523 
treatment. No clear stereoselectivity was observed. 524 
4. The fluoroquinolone qnrS resistance gene was ubiquitous in wastewater. Its removal was 525 
WWTP treatment process dependent with TF performing best and resulting in significant 526 
removal of the gene (from 28 to 75%). Activated sludge and SBRs underperformed with only 527 
9% removal in the case of activated sludge and actual enrichment of the gene during SBR. 528 
Interestingly, the data suggests that higher removal of antibiotic is linked with low removal 529 
of the gene (SBR and WWTP E) and vice versa, low removal of antibiotic is correlated with 530 
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lower prevalence of the gene in wastewater effluent (TF, WWTP B and D). This is especially 531 
prominent in the case of ofloxacin and could indicate that AS might be facilitating AMR 532 
prevalence to higher extent than TF. 533 
5. Exceeding the prescribed use of quinolones is also considered as an AMR driver for enhancing 534 
quinolone resistance. For this reason, an eventual misuse of such class of antibiotics was 535 
evaluated by applying WBE to wastewater analysis data versus official prescription data. 536 
Higher use of S-(-)-ofloxacin was  confirmed by the predominance of the S-(-)-enantiomer of 537 
ofloxacin’s metabolites in wastewater. Hence, these quantities in the environment were 538 
interpreted as resulting from consumption (and not as direct disposal). Ciprofloxacin that was 539 
found with the highest load among quinolones was present in higher amounts with respect to 540 
official statistics. Despite the usage of its metabolite as DTR for ciprofloxacin consumption, 541 
the contribution from veterinary usage needed to be included for accounting for another 542 
ciprofloxacin source.  543 
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Figure 1 Site information of studied WWTPs and corresponding river locations (S refers to the sampling site, R1-8 in the manuscript), WWTP means 






































































































Figure 2 Average daily loads of ofloxacin, ciprofloxacin, norfloxacin and nalidixic acid in wastewater (liquid phase) in the investigated catchment area (sites 



































Figure 3 Average daily loads of ofloxacin and its metabolite desmethylofloxacin in wastewater (liquid phase) during the monitoring week (M -Monday, T – 





































































































































































Figure 4 Daily loads of ofloxacin and its metabolites in wastewater (liquid phase): desmethylofloxacin in WWTPs C and D and ofloxacin-N-oxide in WWTPs 



































































































































































Figure 5 Average daily loads of ofloxacin, ciprofloxacin, norfloxacin and nalidixic acid in SPM from wastewater influent in the investigated catchment area 












































































Figure 6 Percentage removal of ABs and ARG during wastewater treatment in five studied wastewater treatment plants (SBR – Sequencing Batch Reactor; TF 
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Figure 7 Daily loads and population normalised daily loads of Quinolones (ABs: ciprofloxacin, ofloxacin, norfloxacin and nalidixic acid) and qnrS gene in wastewater in 


























































































































































































Table 1. Characteristics of the studied WWTPs contributing to one river catchment area in the South-West UK (a) and wastewater/river water flow rates (b) 



















River sampling: distance to 
discharge point (km) 
Upstream Downstream 
A 37000 <1 <0.5–4 Activated sludge 19 46.2 0.5 n.a. 
B 67870 19 <0.5–4 Trickling filter n.a. 24.5 0.5 0.5 
C 105847 1 <0.5–9 Trickling filter n.a. 13.9 2 2 
D 17638 <1 <0.5–2 Trickling filter n.a. 17.6 1 1 
E 909617 5 <1-24 
90% Sequencing batch 
reactor 




25.8 – – 
(b) Flow rates [m3/day] 
WWTP 
A B C D E 
Waste 

















Mon 15386.1 125625.9 141012.0 13212.0 169092.0 182304.0 29163.4 400032.0 422560.9 3080.0 355363.2 358443.2 181229.0 
Tue 9409.8 132431.2 141841.0 18275.0 328189.0 346464.0 25694.6 384480.0 413643.4 2661.2 321840.0 324501.2 148587.0 
Wed 6386.8 71118.2 77505.0 9527.0 141673.0 151200.0 N.A. 355968.0 381662.6 2604.3 318297.6 320901.9 155494.0 
Thu 6203.9 62145.1 68349.0 9979.0 137765.0 147744.0 23891.2 513216.0 539499.6 2940.5 305164.8 308105.3 151767.0 
Fri 6601.6 110857.4 117459.0 9364.0 130604.0 139968.0 23651.5 454464.0 478355.2 2981.4 340416.0 343397.4 148678.0 
Sat 7017.4 79175.6 86193.0 9558.0 118314.0 127872.0 22914.6 427680.0 451331.5 3184.9 315100.8 318285.7 143128.0 








Table 2. Comparison of consumption estimates between prescriptions data and wastewater (WW) analysis. 
Pharmaceuticals Total consumption (kg/year) in England DTR CF 
Consumption (intake) estimates (mg day−1 1000 people−1) in England 
NHS data 
(2015) 
WW analysis (2015) 




235 77 249 256 160 
Desethylene-
ciprofloxacin 54.2 915 788 1223 1548 2595 










2 as (±)-OFL 





5 as (±)-OFL 
8 as S-(−)-OFL 
18 as (±)-OFL 
51 as S-(−)-OFL 
Ofloxacin-N-oxide 47.9 91 as S-(−)-OFL N.d. N.d. N.d. 







16 as (±)-OFL 
19 as S-(−)-OFL 
193 S-(−)-
OFL 




Norfloxacin 1.1 Norfloxacin 3.07 0.1 N.d. 61 N.d. 101 172 
Nalidixic acid – Nalidixic acid 2.50 0.3 3 3 3 2 14 




N.d. N.d. N.d. 16 17 
Moxifloxacin-N-




– – – – – 
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Figure S1 All (fluoro)quinolones selected in the study (* indicates the position of the chiral center). 
The arrow indicates that the produced analyte is a metabolite (to be noticed that not all the metabolites 
























































































































Table S1 Quinolones-info on their chirality and the marketed form use (n.a. not available). 
 


























































Ciprofloxacin N - - 
Ofloxacin Y Racemate - 
L-Ofloxacin  Y Single enantiomer - 
Pefloxacin N - Not approved in the USA 
Enoxacin N - Withdrawn in the USA 
Temafloxacin Y Racemate Not marketed in Europe 
Norfloxacin N - - 
Lomefloxacin Y Racemate* - 
Fleroxacin N - Withdrawn 
Sparfloxacin Y Single enantiomer Withdrawn 
Rufloxacin N - - 
Grepafloxacin Y Racemate Withdrawn 
Trovafloxacin Y n.a. Withdrawn 
Moxifloxacin Y Single enantiomer - 
Gemifloxacin Y Racemate Not approved in Europe (Korea only) 
Gatifloxacin Y Racemate Available only in the US and Canada 
Prulifloxacin Y Racemate - 
Pazufloxacin Y Single enantiomer Marketed only in Japan 
Garenoxacin Y Single enantiomer Available in Korea, Japan and China 
Sitafloxacin Y Single enantiomer Marketed only in Japan 
Rosoxacin N - Not available in theUSA 
Nalidixic acid N - - 
Piromidic acid N - n.a. 
Pipemidic acid N - - 
Oxolinic acid N - n.a. 
Cinoxacin N - - 
Flumequine Y Racemate - 










Nadifloxacin Y Racemate - 
Besifloxacin Y Single enantiomer - 
Danofloxacin Y Maybe single enantiomer Not marketed in Europe 
Orbifloxacin** Y  Not marketed in Europe 
Ibafloxacin Y Racemate Not marketed in Europe 
Pradofloxacin Y Single enantiomer - 
Balofloxacin Y n.a. Available only in Korea 
Tosufloxacin Y Racemate Marketed only in Japan 
Marbofloxacin N - - 
Difloxacin N - - 
Enrofloxacin N - - 
* A patent of R-lomefloxacin is also available 




Table S2 Selected analytes and their properties (MW=molecular weight). 






Ciprofloxacin 85721-33-1 C17H18FN3O3 331.3 -0.81a 5.76a 8.68a Fluka 
Desethylene-ciprofloxacin 528851-31-2 C₁₅H₁₇ClFN₃O₃ 341.8 - - - TRC 
S-(-)-Ofloxacin 
(L-Ofloxacin) 
100986-85-4 C18H20FN3O4  0.65a 5.45a 6.20a Sigma Aldrich 
(±)-Ofloxacin 82419-36-1 C18H20FN3O4 361.4 0.65a 5.45a 6.20a Sigma Aldrich 
Norfloxacin 70458-96-7 C16H18FN3O3 319.3 -0.92a 5.77a 8.68a Fluka 
(±)-Ofloxacin-N-oxide 104721-52-0 C₂₀H₂₄FN₃O₇ 437.4 - - - TRC 
(±)-Desmethyl-ofloxacin 82419-52-1 C₁₇H₁₈FN₃O₄ 347.3 - - - TRC 
Nalidixic acid 3374-05-8 C12H11N2NaO3 254.2 1.01a 5.95a 4.68a Sigma Aldrich 
(±)-Lomefloxacin 98079-52-8 C17H19F2N3O3  -0.30e 5.64e 8.70e Sigma Aldrich 
R,R-(+)-Moxifloxacin 1346603-25-5 C₂₁H₂₅ClFN₃O₄ 437.9 2.9e 5.69a 9.42a TRC 
S,S-(-)-Moxifloxacin 192927-63-2 C₂₁H₂₇ClFN₃O₅ 455.9 2.9e 5.69a 9.42a TRC 
Moxifloxacin-N-sulphate n.a. C₂₁H₂₂FN₃Na₂O₇S 525.5 - - - TRC 
(±)-Prulifloxacin 123447-62-1 C21H20FN3O6S 461.5 2.49b 
3.27c 
5.85d 6.25d Sigma Aldrich 
(±)-Ulifloxacin 112984-60-8 C₁₆H₁₆FN₃O₃S 349.4 -0.56d 5.85d 8.69d TRC 
(±)-Flumequine 42835-25-6 C14H12FNO3  2.42a 6.00e -4.30e Sigma Aldrich 
(±)-Nadifloxacin 124858-35-1 C₁₉H₂₁FN₂O₄ 360.4 1.87d 5.55d 1.27d TRC 




















M2 ratio ± 
SD 
Internal standard 
Ciprofloxacin 42/40 332.2 > 231.1 42/32 332.2 > 245.1 8.9 ± 2.2 Ciprofloxacin –D8 
Desethylene-ciprofloxacin 40/34 306.3 > 217.1 40/26 306.3 > 268.0 1.4 ± 0.4 Ciprofloxacin –D8 
S-(-)-Ofloxacin (L-
Ofloxacin) 
20/32 362.2 > 261.2 20/32 362.2 > 318.7 29.6 ± 3.4 S-(-)-Ofloxacin-D3 
R-(+)-Ofloxacin 20/32 362.2 > 261.2 20/32 362.2 > 318.7 30.0 ± 3.0 R-(+)-Ofloxacin-D3 
Norfloxacin 58/26 320.2 > 233.1 58/38 320.2 > 204.9 2.6 ± 0.5 Ciprofloxacin –D8 
S-(-)-Ofloxacin-N-oxide 28/18 378.3 > 316.7 28/44 378.3 > 246.9 2.7 ± 0.2 S-(-)-Ofloxacin-D3 
R-(+)-Ofloxacin-N-oxide 28/18 378.3 > 316.7 28/44 378.3 > 246.9 2.9 ± 0.4 R-(+)-Ofloxacin-D3 
S-(-)-Desmethyl-ofloxacin 50/26 348.2 > 261.0 50/33 348.2 > 221.0 7.1 ± 0.6 S-(-)-Desmethyl-ofloxacin-D8 
R-(+)-Desmethyl-ofloxacin 50/26 348.2 > 261.0 50/33 348.2 > 221.0 7.2 ± 0.7 R-(+)-Desmethyl-ofloxacin-D8 
Nalidixic acid 30/28 233.2 > 187.0 30/28 233.2 > 215.1 5.6 ± 0.3 Ciprofloxacin –D8 
(±)-Lomefloxacin 22/24 352.0 > 265.0 22/22 352.0 > 308.0 3.0 ± 0.2 Ciprofloxacin –D8 
R,R-(+)-Moxifloxacin 54/27 402.2 > 364.0 54/23 402.2 > 261.0  S-(-)-Desmethyl-ofloxacin-D8 
S,S-(-)-Moxifloxacin 54/27 402.2 > 364.0 54/23 402.2 > 261.0  R-(+)-Desmethyl-ofloxacin-D8 
Moxifloxacin-N-sulphate 54/27 402.2 > 364.0 54/28 402.2 > 341.0 2.8 ± 0.8 S-(-)-Desmethyl-ofloxacin-D8 
Prulifloxacin-E1 42/22 462.2 > 444.1 42/32 462.2 > 360.1 1.2 ± 0.1 S-(-)-Ofloxacin-D3 
Prulifloxacin-E2 42/22 462.2 > 444.1 42/32 462.2 > 360.1 1.2 ± 0.2 R-(+)-Ofloxacin-D3 
Ulifloxacin-E1 42/22 350.2 > 306.4 42/26 350.2 > 263.0 1.2 ± 0.3 S-(-)-Desmethyl-ofloxacin-D8 
Ulifloxacin-E2 42/22 350.2 > 306.4 42/26 350.2 > 263.0 1.2 ± 0.2 R-(+)-Desmethyl-ofloxacin-D8 
Flumequine-E1 28/34 262.2 > 201.9 28/26 262.2 > 244.5 1.7 ± 0.1 Flumequine-13C3-E1 
Flumequine-E2 28/34 262.2 > 201.9 28/26 262.2 > 244.5 1.8 ± 0.2 Flumequine-13C3-E2 
Nadifloxacin-E1 40/38 361.3 > 282.9 40/44 361.3 > 256.8 1.6 ± 0.1 Flumequine-13C3-E1 
Nadifloxacin-E2 40/38 361.3 > 282.9 40/44 361.3 > 256.8 1.6 ± 0.2 Flumequine-13C3-E2 





    
Ciprofloxacin –D8 30/26 340.1 > 296.1     
S-(-)-Ofloxacin-D3 47/28 365.2 > 261.0     
R-(+)-Ofloxacin-D3 47/28 365.2 > 261.0     
S-(-)-Desmethyl-ofloxacin-
D8 
64/32 356.6 > 265.1     
R-(+)-Desmethyl-ofloxacin-
D8 
64/32 356.6 > 265.1     
Flumequine-13C3-E1 40/24 265.1 > 246.9     
Flumequine-13C3-E2 40/24 265.1 > 246.9     











Waters ACQUITY UPLC® system (Waters, Manchester, UK) 
Column: chiral CHIRALCEL® OZ-RH column (5 μm particle size, L × I.D. 15 
cm × 2.1 mm, Chiral Technologies, France)  
Column temperature: 30ᵒC 
Autosampler temperature: 4ᵒC 
Mobile phase: Isocratic. 10 mM ammonium formate/methanol 1:99 v/v with 
0.05% formic acid 
Flow rate: 0.1 ml min-1 
Injection volume: 20 μl 
MASS SPECTROMETRY 
Xevo TQD (Triple quadrupole mass spectrometer, Waters, Manchester, UK) 
Source: Electrospray ionisation (ESI) 
Mode: POS 
Capillary voltage: 3 kV 
Source temperature: 350ᵒC 
Desolvation temperature: 350ᵒC 
Desolvation gas flow: 650 L h-1 
Nebulising and desolvation gas: Nitrogen (Peak Scientific, UK) 
Collision gas: Argon 
SOLID PHASE EXTRACTION 
Cartridge: Waters Oasis HLB 
Conditioning: 3 ml methanol followed by 3 ml ultrapure water (3 ml min-1) 
Loading: 50 ml samples (8 ml min-1) 
Elution: 4 ml methanol (3 ml min-1) 
SI7 
 
Table S4 Validation parameters - enantiomeric fraction (EF) of compounds, which stereoisomers 
were separated under studied conditions, at three concentrations.  
 
Compounds EF (n=9) 
5 µg/L 50 µg/L 500 µg/L 
(±)-Ofloxacin 0.53±0.01 0.49±0.01 0.49±0.00 
(±)-Ofloxacin-N-oxide 0.49±0.01 0.48±0.01 0.50±0.01 
(±)-Desmethyl-ofloxacin 0.50±0.04 0.51±0.02 0.51±0.01 
(±)-Prulifloxacin 0.49±0.04 0.41±0.01 0.47±0.02 
(±)-Ulifloxacin 0.51±0.01 0.49±0.01 0.49±0.01 
(±)-Flumequine 0.51±0.03 0.50±0.02 0.49±0.02 
(±)-Nadifloxacin 0.51±0.02 0.52±0.01 0.50±0.02 







Table S5 Validation parameters - retention time, relative retention time, linearity range, correlation coefficient obtained from calibration curve and 






























Ciprofloxacin 8.7 ± 0.1 2.5 0.05-1000 0.9945 0.050 0.100 0.6 1.1 0.5 1.1 0.6 1.2 0.04 0.07 
Desethylene-ciprofloxacin 6.6 ± 1.1 1.3 5.0-1000 0.9906 5.000 5.000 54.3 54.3 70.3 70.3 81.4 81.4 9.06 9.06 
S-(-)-Ofloxacin  13.1 ± 0.1 0.2 0.25-1000 0.9983 0.250 0.250 2.2 2.2 2.6 2.6 2.7 2.7 0.08 0.08 
R-(+)-Ofloxacin 18.3 ± 0.5 2.5 0.25-1000 0.9973 0.250 0.250 2.3 2.3 2.6 2.6 2.6 2.6 0.09 0.09 
Norfloxacin 9.0 ± 0.3 4.1 0.25-1000 0.9900 0.250 5.000 3.1 62.6 2.9 58.7 2.8 55.5 0.16 3.22 
S-(-)-Ofloxacin-N-oxide 20.3 ± 0.2 0.5 0.5-1000 0.9981 0.500 1.000 4.8 9.6 6.4 12.9 5.9 11.7 4.90 9.80 
R-(+)-Ofloxacin-N-oxide 29.2 ± 0.5 1.8 0.5-1000 0.9974 0.500 1.000 5.5 10.9 6.4 12.8 6.1 12.2 22.73 45.45 
S-(-)-Desmethyl-ofloxacin 7.8 ± 0.1 0.4 0.125-1000 0.9985 0.125 0.500 1.2 5.0 1.6 6.6 1.7 6.7 0.28 1.13 
R-(+)-Desmethyl-ofloxacin 9.9 ± 0.1 0.4 0.125-1000 0.9982 0.125 0.500 1.3 5.1 1. 7 6.7 1.7 6.7 0.31 1.24 
Nalidixic acid 14.5 ± 0.1 2.9 0.01-2000 0.9940 0.010 0.025 0.1 0.3 0.1 0.3 0.1 0.2 0.01 0.02 
(±)-Lomefloxacin 8.8 ± 0.1 2.6 0.25-2000 0.9981 0.250 0.250 2.6 2.6 3.1 3.1 2.7 2.7 0.18 0.18 
R,R-(+)-Moxifloxacin 8.3 ± 0.1 0.7 0.5-1000 0.9902 0.500 0.500 4.2 4.2 5.8 5.8 4.7 4.7 0.40 0.40 
S,S-(-)-Moxifloxacin 9.0 ± 0.1 0.6 0.5-1000 0.9914 0.500 0.500 6.4 6.4 6.6 6.6 5.1 5.1 0.31 0.31 
Moxifloxacin-N-sulphate 13.6 ± 0.2 1.7 0.5-2000 0.9941 0.500 1.000 5.7 11.3 5.2 10.4 5.2 10.3 1.13 2.25 
Prulifloxacin-E1 23.4 ± 0.9 2.4 0.5-1000 0.9969 0.500 0.500 5.8 5.8 5.7 5.7 7.0 7.0 0.28 0.28 
Prulifloxacin-E2 26.5 ± 0.5 2.5 0.5-1000 0.9966 0.500 0.500 5.1 5.1 6.2 6.2 7.0 7.0 0.27 0.27 
Ulifloxacin-E1 9.0 ± 0.6 6.1 2.5-1000 0.9981 2.500 2.500 23.5 23.5 35.1 35.1 33.9 33.9 1.19 1.19 
Ulifloxacin-E2 11.2 ± 0.9 7.8 2.5-1000 0.9950 2.500 2.500 33.9 33.9 36.2 36.2 28.7 28.7 1.16 1.16 
Flumequine-E1 12.9 ± 0.1 0.2 0.025-1000 0.9991 0.025 0.500 0.3 5.3 0.3 5.4 0.3 5.3 0.01 0.26 
Flumequine-E2 17.5 ± 0.1 0.1 0.025-1000 0.9978 0.025 0.500 0.3 5.3 0.3 5.3 0.3 5.3 0.01 0.25 
Nadifloxacin-E1 15.2 ± 0.1 0.3 0.025-1000 0.9989 0.025 0.500 0.2 4.3 0.3 5.6 0.3 5.4 0.01 0.11 
Nadifloxacin-E2 22.4 ± 0.2 0.2 0.025-1000 0.9978 0.025 0.500 0.2 5.0 0.3 5.6 0.3 5.4 0.01 0.12 




Table S6 Validation parameters – average enantiomeric fraction (EF), enantiomeric resolution (Rs) of compounds, which stereoisomers were separated 
under studied conditions, in mobile phase (MP) and in wastewater (WW), precision (RSD %) and accuracy (%). 
 





Accuracy (%) Precision 
(RSD %) 
Accuracy (%) 
Ciprofloxacin - - - 5.0 89.8 8.8 110.0 
Desethylene-ciprofloxacin - - - 8.7 90.9 7.8 83.8 
S-(-)-Ofloxacin (L-Ofloxacin) 1.25 0.89 0.50±0.00 4.5 103.6 4.5 118.3 
R-(+)-Ofloxacin 4.3 101.7 5.7 105.3 
Norfloxacin - - - 8.8 111.3 11.5 83.3 
S-(-)-Ofloxacin-N-oxide 1.71 1.07 0.49±0.00 4.0 100.9 6.2 104.3 
R-(+)-Ofloxacin-N-oxide 9.0 96.0 5.6 91.4 
S-(-)-Desmethyl-ofloxacin 0.97 0.56 0.50±0.01 2.9 102.5 3.9 100.7 
R-(+)-Desmethyl-ofloxacin 6.3 102.8 5.1 97.5 
Nalidixic acid - - - 4.4 96.5 8.0 92.1 
(±)-Lomefloxacin - - - 3.9 94.6 6.7 97.0 
R,R-(+)-Moxifloxacin 0.84 0.21 0.51±0.01 7.7 102.0 9.8 122.4 
S,S-(-)-Moxifloxacin 6.6 93.3 5.3 77.6 
Moxifloxacin-N-sulphate - - - 7.9 101.0 6.0 81.7 
Prulifloxacin-E1 1.06 0.46 0.46±0.01 6.8 88.4 7.2 116.6 
Prulifloxacin-E2 4.7 106.4 7.9 72.4 
Ulifloxacin-E1 0.67 0.41 0.50±0.01 5.8 93.6 10.6 118.0 
Ulifloxacin-E2 7.8 113.8 6.6 101.3 
Flumequine-E1 1.91 1.10 0.50±0.00 2.8 101.8 1.5 94.4 
Flumequine-E2 5.5 102.3 2.9 95.5 
Nadifloxacin-E1 2.86 1.44 0.51±0.01 3.8 107.8 3.4 118.9 
Nadifloxacin-E2 6.7 96.4 6.0 100.2 





Table S7. Matrix effect, absolute and relative SPE recoveries (n=3) for the studied analytes (rec=recovery). 









 25 ng/L* 250 ng/L* 2500 ng/L* 25 ng/L* 250 ng/L* 2500 ng/L* 25 ng/L* 250 ng/L* 2500 ng/L* 
Ciprofloxacin 117.0 46.8 68.2 68.9 84.3 ± 5.7  83.8 ± 1.7 101.7 ± 31.7 78.3 ± 3.5 71.0 ± 1.1 126.4 ± 0.2 72.2 ± 4.8 94.8 ± 2.5 82.9 ± 3.4 
Desethylene-ciprofloxacin 74.6 23.1 40.3 27.6 83.8 ± 8.9 107.7 ± 3.5 84.9 ± 4.5 87.1 ± 2.1 73.7 ± 8.0 52.7 ± 4.1 82.7 ± 1.5 59.0 ± 5.4 42.6 ± 2.9 
S-(-)-Ofloxacin  111.6 81.2 114.8 149.7 110.8 ± 9.3 113.6 ± 1.5 111.9 ± 1.1 91.9 ± 3.8 92.2 ± 4.0 107.5 ± 4.3 109.5 ± 10.3 87.6 ± 0.6 81.4 ± 3.5 
R-(+)-Ofloxacin 107.6 78.3 141.5 135.9 113.8 ± 1.9 98.9 ± 1.8 106.4 ± 2.5 93.8 ± 6.1 89.8 ± 6.7 106.3 ± 0.5 117.8 ± 9.1 85.5 ± 5.0 80.6 ± 3.2 
Norfloxacin 79.2 15.4 271.7 77.7 73.0 ± 3.7 82.0 ± 1.0 84.7 ± 2.6 87.1 ± 3.7 86.3 ± 1.0 82.2 ± 5.6 110.0 ± 2.0 90.4 ± 10.2 70.1 ± 7.2 
S-(-)-Ofloxacin-N-oxide 108.7 79.0 124.3 5.1 103.1 ± 5.1 106.7 ± 6.2 103.0 ± 2.1 72.8 ± 3.4 84.3 ± 4.1 76.2 ± 2.6 98.6 ± 8.8 80.4 ± 3.0 77.1 ± 1.0 
R-(+)-Ofloxacin-N-oxide 102.9 75.1 168.0 1.1 82.2 ± 11.9 95.2 ± 3.0 96.7 ± 2.0 72.8 ± 7.3 83.3 ± 3.7 78.5 ± 7.2 95.4 ± 4.2 76.7 ± 7.6 74.1 ± 2.1 
S-(-)-Desmethyl-ofloxacin 96.3 37.6 67.8 22.1 97.1 ± 9.1 103.1 ± 3.5 101.8 ± 3.9 75.0 ± 1.4 82.3 ± 1.5 70.4 ± 0.9 74.7 ± 1.4 76.8 ± 2.1 73.4 ± 0.7 
R-(+)-Desmethyl-ofloxacin 95.6 32.0 129.8 20.2 111.3 ± 11.7 88.8 ± 2.9 92.4 ± 2.2 72.3 ± 4.1 79.3 ± 5.3 73.2 ± 1.0 76.4 ± 2.8 75.6 ± 3.3 72.1 ± 2.8 
Nalidixic acid 98.6 63.8 112.6 61.5 89.8 ± 7.9 89.3 ± 10.8 90.1 ± 12.7 90.3 ± 2.3 103.1 ± 
4.3 
94.0 ± 1.7 105.6 ± 5.4 109.2 ± 4.7 98.7 ± 7.5 
(±)-Lomefloxacin 90.8 36.1 99.6 68.9 102.9 ± 6.0 90.4 ± 1.0 97.6 ± 1.2 78.4 ± 5.3 87.0 ± 4.3 76.4 ± 4.3 101.4 ± 2.4 98.9 ± 4.5 80.4 ± 4.5 
R,R-(+)-Moxifloxacin 104.0 86.3 70.5 61.8 118.0 ± 0.8 118.7 ± 1.4 117.3 ± 0.9 81.6 ± 4.5 94.5 ± 5.0 84.4 ± 2.9 118.5 ± 12.4 104.7 ± 5.5 94.2 ± 9.5 
S,S-(-)-Moxifloxacin 90.0 61.1 87.9 80.7 78.4 ± 5.6 71.7 ± 6.9 85.7 ± 7.5 75.9 ± 7.5 78.3 ± 4.4 72.6 ± 2.8 113.3 ± 17.0 91.9 ± 3.0 89.5 ± 2.8 
Moxifloxacin-N-sulphate 116.4 45.5 88.8 22.2 85.2 ± 4.0 82.5 ± 2.8 96.9 ± 3.6 92.4 ± 2.6 108.9 ± 
2.0 
88.0 ± 7.5 101.3 ± 12.7 105.6 ± 14.0 83.2 ± 9.3 
Prulifloxacin-E1 109.0 132.4 73.5 89.3 73.3 ± 2.8 81.9 ± 8.2 105.1 ± 5.7 63.6 ± 4.5 81.9 ± 8.2 119.7 ± 4.9 73.3 ± 2.8 81.9 ± 8.2 105.1 ± 5.7 
Prulifloxacin-E2 102.2 74.6 144.4 91.2 97.8 ± 20.4 96.8 ± 3.8 100.7 ± 3.4 66.5 ± 6.8 82.4 ± 1.7 91.9 ± 4.1 97.8 ± 20.4 96.8 ± 3.8 100.7 ± 3.4 
Ulifloxacin-E1 119.1 47.8 92.5 105.0 119.0 ± 0.5 98.6 ± 3.5 101.1 ± 4.5 72.9 ± 3.8 73.8 ± 1.1 67.1 ± 1.0 71.9 ± 2.6 71.5 ± 3.6 77.7 ± 0.9 
Ulifloxacin-E2 73.8 20.8 274.1 108.0 80.7 ± 9.3 70.3 ± 0.3 70.5 ± 0.5 80.4 ± 9.5 60.1 ± 3.8 66.9 ± 4.7 98.2 ± 16.0 83.9 ± 10.1 79.5 ± 4.1 
Flumequine-E1 98.3 66.5 136.8 96.3 90.2 ± 2.7 95.0 ± 1.1 95.9 ± 0.1 90.1 ± 1.6 99.2 ± 1.3 86.3 ± 1.7 101.3 ± 1.3 93.0 ± 3.1 86.2 ± 0.7 
Flumequine-E2 97.8 70.8 155.6 101.4 89.3 ± 1.8 96.4 ± 0.3 98.4 ± 0.9 90.4 ± 10.5 105.2 ± 
1.5 
85.9 ± 5.0 102.4 ± 4.5 94.5 ± 14.2 86.3 ± 3.1 
Nadifloxacin-E1 112.3 75.9 119.3 232.8 118.3 ± 0.6 115.6 ± 4.5 116.8 ± 3.0 87.5 ± 3.9 94.5 ± 2.5 86.6 ± 1.6 96.9 ± 2.7 94.9 ± 3.0 83.5 ± 4.0 
Nadifloxacin-E2 111.7 80.9 136.0 206.2 94.9 ± 6.8 98.6 ± 4.7 107.0 ± 4.6 84.2 ± 2.1 97.8 ± 2.6 83.8 ± 5.1 97.3 ± 12.6 95.9 ± 7.4 82.9 ± 8.0 
R-(+)-Besifloxacin 85.6 17.4 221.6 232.1 106.8 ± 2.7 73.5 ± 5.7 72.0 ± 1.6 94.6 ± 2.5 73.0 ± 3.0 66.3 ± 6.8 114.3 ± 6.3 72.6 ± 2.0 70.5 ± 0.1 






Table S8 Concentrations of the analytes in liquid environmental matrices (influent, effluent, river 
upstream and river downstream) during the monitoring week in WWTP A.  
 Ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 198.3 22.5 249.8 22.3 52.0 3.2 109.7 16.5 
Tues 508.4 30.5 505.4 11.9 52.9 3.8 98.7 13.7 
Wed 728.3 109.5 300.3 57.6 42.5 2.6 271.6 8.6 
Thu 579.5 14.7 359.0 41.2 45.5 3.3 209.6 38.6 
Fri 528.8 58.0 308.4 55.5 49.8 0.3 169.9 3.1 
Sat 546.2 30.7 578.0 101.4 42.8 1.1 187.4 2.0 
Sun 421.7 82.0 428.9 124.4 48.9 1.0 213.1 57.0 
 
 Desethylene-ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - <MQL  - <MQL  - 
Tues 53.4 2.0 <MQL  - <MQL  - <MQL  - 
Wed 80.8 6.3 <MQL  - <MQL  - <MQL  - 
Thu 115.2 1.6 <MQL  - <MQL  - <MQL  - 
Fri 91.6 6.7 <MQL  - <MQL  - <MQL  - 
Sat 99.4 5.7 <MQL  - <MQL  - <MQL  - 

















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - 3.7 0.7 <MQL  - <MQL  - 
Tues 58.6 3.1 3.8 0.5 <MQL  - <MQL  - 
Wed 33.2 18.3 7.4 1.8 <MQL  - 4.5 0.8 
Thu 34.0 7.6 8.0 1.9 <MQL  - 4.5 0.0 
Fri 21.1 2.0 4.6 1.0 <MQL  - <MQL  - 
Sat 16.5 4.5 7.8 0.8 <MQL  - 4.1 1.5 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 36.2 7.8 19.7 3.2 <MQL  - 8.6 1.8 
Tues 179.3 8.5 20.3 0.0 <MQL  - 6.1 1.8 
Wed 268.2 91.1 47.0 2.0 <MQL  - 30.9 0.9 
Thu 247.9 2.4 50.5 2.8 2.9 0.4 24.9 3.4 
Fri 209.8 10.8 31.2 6.0 <MQL  - 12.2 0.5 
Sat 186.3 10.3 74.8 12.9 <MQL  - 22.8 0.2 
Sun 115.5 32.6 53.8 31.3 <MQL  - 14.9 5.1 
 
(±)-Ofloxacin-N-Oxide 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - <MQL  - <MQL  - 
Thu n.d.  - n.d.  - <MQL  - <MQL  - 
Fri n.d.  - n.d.  - n.d.  - <MQL  - 
Sat n.d.  - n.d.  - n.d.  - <MQL  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 3.4 0.8 n.d.  - n.d.  - n.d.  - 
Tues 6.9 0.6 n.d.  - n.d.  - n.d.  - 
Wed 15.1 4.5 n.d.  - <MQL  - <MQL  - 
Thu 21.8 5.6 n.d.  - <MQL  - <MQL  - 
Fri 10.8 2.8 n.d.  - <MQL  - <MQL  - 
Sat 6.5 0.4 n.d.  - n.d.  - <MQL  - 







 Nalidixic acid 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.   - 1.1 0.5 n.d.   - 
Tues 0.8 1.3 n.d.   - 0.9 0.3 n.d.   - 
Wed 30.4 25.0 3.5 0.2 1.7 0.0 2.0 0.3 
Thurs n.d.  - 2.9 0.5 1.0 0.0 1.3 0.3 
Fri 7.7 3.0 n.d.   - 1.6 0.3 1.9 0.4 
Sat 8.3 1.7 2.9 0.3 1.1 0.0 1.9 0.3 
Sun 4.4 0.4 n.d.   - 1.2 0.2 0.9 0.1 
 
 Norfloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - 91.9 34.0 134.4 30.6 74.2 20.3 
Tues n.d.  - <MQL  - 113.9 0.2 59.5 2.6 
Wed n.d.  - 73.5 28.1 117.7 12.5 64.8 24.4 
Thurs n.d.  - 74.2 15.2 113.5 13.4 86.5 16.6 
Fri n.d.  - 77.9 10.3 137.0 36.4 71.9 10.2 
Sat n.d.  - 103.0 35.8 127.5 3.4 59.6 30.3 




















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - n.d.  - n.d.  - n.d.  - 
Tues <MQL  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - <MQL  - 
Thu n.d.  - <MQL  - n.d.  - <MQL  - 
Fri n.d.  - <MQL  - n.d.  - <MQL  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - n.d.  - <MQL  - 
Tues <MQL  - <MQL  - n.d.  - n.d.  - 
Wed <MQL  - <MQL  - n.d.  - <MQL  - 
Thu <MQL  - <MQL  - n.d.  - 0.0 0.0 
Fri <MQL  - <MQL  - n.d.  - <MQL  - 
Sat <MQL  - <MQL  - n.d.  - n.d.  - 
Sun <MQL  - <MQL  - n.d.  - <MQL  - 
 
(±)-Flumequine 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - 5.6 0.8 <MQL  - <MQL  - 
Tues <MQL  - 8.2 0.7 <MQL  - <MQL  - 
Wed 8.4 3.4 7.9 0.5 <MQL  - 7.9 2.4 
Thu <MQL  - 6.6 0.1 <MQL  - 5.9 1.7 
Fri <MQL  - 5.5 0.6 <MQL  - 5.5 0.9 
Sat <MQL  - 11.2 1.4 <MQL  - <MQL  - 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - <MQL  - <MQL  - 
Tues <MQL  - n.d.  - <MQL  - <MQL  - 
Wed n.d.  - <MQL  - <MQL  - n.d.  - 
Thu n.d.  - n.d.  - <MQL  - n.d.  - 
Fri n.d.  - n.d.  - <MQL  - n.d.  - 
Sat n.d.  - n.d.  - <MQL  - n.d.  - 




 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Moxifloxacin 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - 8.7 2.5 n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Prulifloxacin 














 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 





Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Ulifloxacin 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
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Table S9 Concentrations of the analytes in liquid environmental matrices (influent, effluent, river 
upstream and river downstream) during the monitoring week in WWTP B.  
 
 Ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 147.8 4.3 152.6 31.1 31.4 10.4 29.0 5.4 
Tues 108.3 17.3 140.0 3.3 24.5 4.1 24.8 4.3 
Wed 269.0 0.5 116.7 23.8 18.0 1.3 28.3 1.4 
Thu 212.8 16.2 98.1 1.8 24.8 3.1 22.5 5.1 
Fri 303.1 15.7 106.9 2.2 16.0 1.1 27.5 3.2 
Sat 247.6 21.3 105.9 20.0 21.8 6.7 24.9 0.1 
Sun 316.2 6.1 99.8 1.3 19.9 2.9 23.6 0.4 
 
 Desethylene-ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 131.3 5.8 74.3 1.8 <MQL  - <MQL  - 
Tues 70.9 1.0 <MQL  - <MQL  - <MQL  - 
Wed 72.8 6.2 <MQL  - <MQL  - <MQL  - 
Thu 85.3 2.8 <MQL  - <MQL  - <MQL  - 
Fri 80.2 0.2 <MQL  - <MQL  - <MQL  - 
Sat 83.0 4.7 <MQL  - <MQL  - <MQL  - 
















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 5.3 0.7 8.3 2.2 <MQL  - <MQL  - 
Tues 6.3 0.7 6.0 0.4 <MQL  - <MQL  - 
Wed 12.1 0.9 7.8 1.6 <MQL  - <MQL  - 
Thu 16.2 0.5 6.3 0.6 <MQL  - <MQL  - 
Fri 18.7 0.3 6.7 0.3 <MQL  - <MQL  - 
Sat 5.4 0.4 5.9 0.8 <MQL  - <MQL  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 9.3 1.9 13.7 2.4 <MQL  - <MQL  - 
Tues 8.0 0.9 12.6 0.9 <MQL  - <MQL  - 
Wed 15.4 5.0 19.9 0.9 <MQL  - 3.0 0.1 
Thu 24.0 1.2 13.7 0.8 3.7 0.3 4.0 2.8 
Fri 25.9 0.6 16.6 2.9 <MQL  - <MQL  - 
Sat 9.6 0.8 12.7 6.3 <MQL  - <MQL  - 
Sun 17.8 1.2 10.6 1.5 <MQL  - <MQL  - 
 
(±)-Ofloxacin-N-Oxide 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - n.d.  - <MQL  - 
Tues <MQL  - <MQL  - n.d.  - <MQL  - 
Wed n.d.  - <MQL  - n.d.  - n.d.  - 
Thu <MQL  - <MQL  - n.d.  - <MQL  - 
Fri n.d.  - <MQL  - n.d.  - <MQL  - 
Sat <MQL  - <MQL  - n.d.  - <MQL  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - n.d.  - n.d.  - 
Tues <MQL  - <MQL  - n.d.  - n.d.  - 
Wed <MQL  - <MQL  - <MQL  - <MQL  - 
Thu <MQL  - <MQL  - n.d.  - <MQL  - 
Fri <MQL  - <MQL  - n.d.  - n.d.  - 
Sat <MQL  - <MQL  - n.d.  - <MQL  - 







 Nalidixic acid 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 8.4 1.9 16.5 2.7 1.2 0.6 1.3 0.6 
Tues 1.0 0.1 16.5 2.0 0.9 0.1 1.3 0.3 
Wed 5.0 0.9 17.7 4.0 1.2 0.4 2.2 0.0 
Thurs 14.4 0.9 15.6 2.4 1.2 0.0 1.5 0.0 
Fri 7.9 0.3 17.9 0.8 0.9 0.1 2.2 0.7 
Sat 8.7 0.2 14.4 3.5 1.0 0.3 2.7 0.1 
Sun 14.3 1.5 14.1 0.7 0.7 0.2 2.4 0.0 
 
 Norfloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 139.4 85.6 84.6 7.4 67.3 28.0 <MQL  - 
Tues 94.0 10.7 90.9 10.4 81.8 11.7 <MQL  - 
Wed 171.1 40.7 85.1 21.5 <MQL  - <MQL  - 
Thurs 150.1 68.7 86.0 2.1 <MQL  - <MQL  - 
Fri 99.9 47.3 63.7 22.7 <MQL  - <MQL  - 
Sat 112.5 11.9 79.8 49.2 <MQL  - <MQL  - 




















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed 15.6 11.0 n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - <MQL  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed 18.5 13.1 n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Flumequine 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - 10.3 2.2 <MQL  - <MQL  - 
Tues <MQL  - 9.6 1.6 <MQL  - <MQL  - 
Wed <MQL  - 7.1 0.8 <MQL  - <MQL  - 
Thu <MQL  - 8.8 1.7 <MQL  - <MQL  - 
Fri <MQL  - 9.6 0.9 <MQL  - <MQL  - 
Sat <MQL  - 11.0 1.8 <MQL  - <MQL  - 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - <MQL  - n.d.  - n.d.  - 
Tues <MQL  - <MQL  - n.d.  - <MQL  - 
Wed <MQL  - <MQL  - <MQL  - n.d.  - 
Thu n.d.  - n.d.  - <MQL  - n.d.  - 
Fri <MQL  - <MQL  - n.d.  - n.d.  - 
Sat <MQL  - n.d.  - n.d.  - <MQL  - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - <MQL  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - <MQL  - 
Thu <MQL  - n.d.  - <MQL  - n.d.  - 
Fri <MQL  - n.d.  - n.d.  - <MQL  - 
Sat <MQL  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed <MQL  - <MQL  - <MQL  - n.d.  - 
Thu <MQL  - n.d.  - n.d.  - n.d.  - 
Fri <MQL  - n.d.  - n.d.  - <MQL  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun <MQL  - n.d.  - <MQL  - <MQL  - 
 
(±)-Moxifloxacin 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Ulifloxacin 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
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Table S10 Concentrations of the analytes in liquid environmental matrices (influent, effluent, river 
upstream and river downstream) during the monitoring week in WWTP C.  
 
 Ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 248.0 70.7 128.0 12.7 13.5 0.0 21.3 3.2 
Tues 370.5 6.4 99.0 9.9 19.3 11.7 19.0 1.4 
Wed - - - - 12.3 0.4 21.8 7.4 
Thu 570.0 199.4 110.5 0.7 17.5 3.5 24.5 0.7 
Fri 771.0 297.0 89.5 2.1 18.3 9.5 23.5 2.8 
Sat 511.5 16.3 121.5 26.2 12.3 0.4 19.5 1.4 
Sun 490.0 21.2 136.0 31.1 11.5 0.0 19.3 5.3 
 
 Desethylene-ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 114.0 22.63 - - - - - - 
Tues 112.5 3.54 - - - - - - 
Wed - - - - - - - - 
Thu 86.5 10.61 - - - - - - 
Fri 85.0 120.21 - - - - - - 
Sat 131.5 17.68 - - - - - - 
















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 18.0 4.2 10.5 2.1 <MQL - <MQL - 
Tues 17.5 3.5 9.5 0.7 <MQL - <MQL - 
Wed - - - - <MQL - <MQL - 
Thu 74.0 21.2 17.0 0.0 3.5 1.4 3.0 0.7 
Fri 35.5 0.7 13.0 1.4 <MQL - <MQL - 
Sat 57.5 10.6 12.5 3.5 2.5 1.4 <MQL - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 40.0 2.8 28.5 0.7 <MQL - 3.0 1.4 
Tues 71.0 4.2 21.0 4.2 <MQL - <MQL - 
Wed - - - - <MQL 0.0 4.3 1.1 
Thu 159.0 49.5 29.0 4.2 3.5 2.8 5.8 1.1 
Fri 108.0 2.8 23.0 0.0 <MQL - 3.0 0.0 
Sat 122.5 30.4 31.0 8.5 2.3 1.8 2.3 0.4 
Sun 101.0 1.4 38.5 12.0 <MQL - <MQL - 
 
(±)-Ofloxacin-N-Oxide 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 0 0.0 <MQL - <MQL - 0.0 0.0 
Tues 0 0.0 0.0 0.00 0.0 0.00 0.0 0.0 
Wed - - - - 0.0 0.00 0.0 0.0 
Thu <MQL  <MQL - 0.0 0.00 0.0 0.0 
Fri 0 0.0 <MQL - <MQL - 0.0 0.0 
Sat <MQL - <MQL - 0.0 0.00 <MQL - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL - <MQL - 0 0.00 <MQL - 
Tues 0 0.0 <MQL - <MQL - 0 0.0 
Wed - - - - <MQL - 0 0.0 
Thu 0 0.0 <MQL - <MQL - 0 0.0 
Fri <MQL - <MQL - <MQL - 0 0.0 
Sat <MQL - <MQL - <MQL - <MQL - 







 Nalidixic acid 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon < MQL - 2.5 0.7 1.0 0.0 1.5 0 
Tues - - 2.5 0.7 1.5 1.4 1.0 0 
Wed - - - - 1.0 0.0 0.7 0.3 
Thurs 32.0 17.0 3.5 0.7 1.5 0.7 1.2 0.3 
Fri - - 2.0 0.0 1.3 0.3 1.5 0 
Sat - - 2.0 0.0 0.8 0.3 1.5 0 
Sun - - 2.0 0.0 0.5 0.0 1.0 0 
 
 Norfloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon - - <MQL - <MQL - - - 
Tues - - 68.0 29.7 <MQL - - - 
Wed - - - - <MQL - - - 
Thurs - - <MQL - <MQL - - - 
Fri - - <MQL - <MQL - - - 
Sat - - <MQL - <MQL - - - 




















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL - <MQL - <MQL - <MQL - 
Tues <MQL - <MQL - <MQL - - - 
Wed - - - - <MQL - - - 
Thu <MQL - <MQL - 3.50 1.4 <MQL - 
Fri <MQL - <MQL - <MQL - - - 
Sat <MQL - <MQL - 2.50 1.4 - - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon - - 11.5 3.5 - - - - 
Tues 11.5 2.1 15.5 2.1 - - - - 
Wed - - - - - - - - 
Thu - - <MQL - - - - - 
Fri 51.5 2.1 13 1.4 - - - - 
Sat 36.5 3.5 <MQL - - - - - 
Sun 18 2.8 16 4.2 - - - - 
 
(±)-Flumequine 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 8 1.4 <MQL - <MQL - <MQL - 
Tues 17 1.4 <MQL - <MQL - <MQL - 
Wed - - - - <MQL - <MQL - 
Thu 28 5.7 <MQL - <MQL - <MQL - 
Fri <MQL - <MQL - <MQL - <MQL - 
Sat 7 1.4 <MQL - <MQL - <MQL - 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon - - <MQL - <MQL - <MQL - 
Tues <MQL - <MQL - <MQL - <MQL - 
Wed - - - - <MQL - <MQL - 
Thu 13.5 3.5 <MQL - <MQL - <MQL - 
Fri - - <MQL - <MQL - <MQL - 
Sat <MQL - <MQL - <MQL - <MQL - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon - - 3.5 0.707 <MQL - <MQL - 
Tues - - <MQL - <MQL - <MQL - 
Wed - - - - <MQL - <MQL - 
Thurs - - 4 0.0 2.8 - 3 0.00 
Fri - - <MQL - <MQL - <MQL - 
Sat - - <MQL - <MQL - <MQL - 




 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon <MQL - - - - - - - 
Tues <MQL - <MQL - <MQL - - - 
Wed - - - - <MQL - - - 
Thu 36.0 33.9 <MQL - <MQL - <MQL - 
Fri <MQL - <MQL - - - - - 
Sat <MQL - <MQL - - - - - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon - - - - - - - - 
Tues - - - - <MQL - - - 
Wed - - - - - - - - 
Thu 15.5 10.6 <MQL - <MQL - - - 
Fri <MQL - <MQL - - - <MQL - 
Sat - - <MQL - - - <MQL - 
Sun - - <MQL - - - - - 
 
(±)-Moxifloxacin 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Ulifloxacin 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
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Table S11 Concentrations of the analytes in liquid environmental matrices (influent, effluent, river 
upstream and river downstream) during the monitoring week in WWTP D.  
 
 Ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 1763.8 10.0 255.5 32.0 52.9 1.2 45.3 0.9 
Tues 739.5 162.3 241.2 33.0 48.4 3.5 44.1 0.4 
Wed 502.5 107.9 282.1 23.1 45.5 2.4 41.8 0.3 
Thu 439.2 163.3 257.1 95.3 57.2 3.8 45.1 1.0 
Fri 264.9 43.4 212.7 28.7 57.4 5.9 43.7 0.4 
Sat 366.2 60.9 279.6 109.5 55.1 14.1 48.7 0.6 
Sun 749.7 33.6 225.1 11.6 44.8 6.9 41.3 0.8 
 
 Desethylene-ciprofloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 298.2 63.4 <MQL  - n.d.  - n.d.  - 
Tues 135.6 24.5 <MQL  - n.d.  - n.d.  - 
Wed 111.7 37.4 <MQL  - n.d.  - n.d.  - 
Thu 196.5 47.7 <MQL  - n.d.  - n.d.  - 
Fri 105.7 16.2 <MQL  - n.d.  - n.d.  - 
Sat 148.4 26.2 <MQL  - n.d.  - n.d.  - 
















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 27.5 1.4 10.2 3.7 <MQL  - <MQL  - 
Tues 8.1 0.0 10.0 0.5 <MQL  - <MQL  - 
Wed 6.1 0.7 7.2 0.3 <MQL  - <MQL  - 
Thu 41.8 17.9 17.8 3.3 3.2 1.0 4.9 0.4 
Fri 48.8 1.1 15.5 2.1 2.8 0.7 2.6 0.3 
Sat 18.9 3.7 15.0 6.9 2.7 1.1 <MQL  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 57.0 5.2 20.2 7.0 3.7 0.2 4.3 0.4 
Tues 14.2 0.5 20.3 0.1 3.9 0.7 4.7 1.0 
Wed 10.8 3.4 14.4 2.6 4.3 1.1 3.6 0.5 
Thu 73.4 22.4 36.4 10.4 7.8 1.1 7.8 0.3 
Fri 73.3 2.0 28.1 4.6 5.8 0.6 5.3 0.7 
Sat 32.3 1.6 26.4 11.1 7.3 4.3 3.8 0.4 
Sun 22.5 2.0 22.3 2.3 4.3 2.6 3.2 0.1 
 
(±)-Ofloxacin-N-Oxide 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - <MQL  - n.d.  - n.d.  - 
Fri <MQL  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - <MQL  - n.d.  - <MQL  - 
Tues n.d.  - <MQL  - n.d.  - <MQL  - 
Wed n.d.  - <MQL  - n.d.  - n.d.  - 
Thu <MQL  - <MQL  - n.d.  - <MQL  - 
Fri <MQL  - <MQL  - n.d.  - <MQL  - 
Sat n.d.  - <MQL  - <MQL  - <MQL  - 







 Nalidixic acid 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 12.5 10.9 ,MQL  - 0.9 0.4 1.5 0.0 
Tues 5.9 2.6 1.2 1.7 1.3 0.4 1.9 0.2 
Wed 5.5 1.0 2.1 0.7 1.3 0.1 1.3 0.3 
Thurs 2.3 3.2 2.5 1.1 1.8 1.0 1.6 0.5 
Fri 3.0 1.3 0.9 1.2 1.9 0.6 1.0 0.1 
Sat 1.8 0.0 2.0 2.9 1.8 1.0 2.4 0.6 
Sun 1.7 2.4 2.1 1.7 1.2 1.0 1.5 0.3 
 
 Norfloxacin 
 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 336.1 27.4 154.3 29.9 94.7 5.0 96.0 1.7 
Tues 419.4 24.7 86.7 25.5 65.1 19.0 108.4 8.9 
Wed 127.0 35.9 137.6 35.3 103.1 8.4 93.2 11.1 
Thurs 99.7 5.5 135.9 17.3 65.4 47.2 86.3 17.8 
Fri <MQL  - 144.4 20.0 122.7 21.3 94.3 0.2 
Sat 335.1 42.9 141.0 30.3 134.1 61.7 93.4 54.4 




















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 11.9 8.9 <MQL  - n.d.  - n.d.  - 
Tues 10.3 4.3 <MQL  - n.d.  - n.d.  - 
Wed 6.8 9.6 <MQL  - n.d.  - n.d.  - 
Thu <MQL  - n.d.  - n.d.  - n.d.  - 
Fri <MQL  - <MQL  - n.d.  - n.d.  - 
Sat <MQL  - 9.7 3.4 n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 52.0 14.1 31.4 23.4 n.d.  - n.d.  - 
Tues 70.5 69.6 12.3 8.5 n.d.  - n.d.  - 
Wed 42.3 3.5 27.4 2.5 n.d.  - n.d.  - 
Thu 13.4 18.9 10.1 8.6 n.d.  - n.d.  - 
Fri 19.6 27.7 8.8 2.8 n.d.  - n.d.  - 
Sat 42.8 32.3 <MQL  - n.d.  - n.d.  - 
Sun 36.3 2.0 11.1 1.4 n.d.  - n.d.  - 
 
(±)-Flumequine 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 6.9 9.7 11.6 3.5 <MQL  - <MQL  - 
Tues 13.5 5.5 10.1 1.2 <MQL  - <MQL  - 
Wed 14.5 6.6 9.0 1.8 <MQL  - <MQL  - 
Thu 13.2 3.7 11.7 4.2 <MQL  - <MQL  - 
Fri 6.0 0.4 11.8 2.0 <MQL  - <MQL  - 
Sat 7.9 3.3 13.6 6.7 <MQL  - <MQL  - 








 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon 5.6 1.3 <MQL  - <MQL  - <MQL  - 
Tues <MQL  - <MQL  - <MQL  - <MQL  - 
Wed <MQL  - <MQL  - <MQL  - <MQL  - 
Thu 6.6 2.1 <MQL  - <MQL  - <MQL  - 
Fri <MQL  - <MQL  - <MQL  - <MQL  - 
Sat <MQL  - <MQL  - <MQL  - <MQL  - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 





 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat <MQL  - <MQL  - n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - <MQL  - <MQL  - 
Fri n.d.  - n.d.  - n.d.  - <MQL  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Moxifloxacin 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu 44.1 13.1 <MQL  - n.d.  - n.d.  - 
Fri 23.4 4.1 <MQL  - n.d.  - n.d.  - 
Sat 41.1 25.4 <MQL  - n.d.  - n.d.  - 









 Influent Effluent River Upstream River Downstream 
  Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 















Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
 
(±)-Ulifloxacin 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD Conc. (ng/L) SD  Conc. (ng/L) SD 
Mon n.d.  - n.d.  - n.d.  - n.d.  - 
Tues n.d.  - n.d.  - n.d.  - n.d.  - 
Wed n.d.  - n.d.  - n.d.  - n.d.  - 
Thu n.d.  - n.d.  - n.d.  - n.d.  - 
Fri n.d.  - n.d.  - n.d.  - n.d.  - 
Sat n.d.  - n.d.  - n.d.  - n.d.  - 
Sun n.d.  - n.d.  - n.d.  - n.d.  - 
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Table S12 Concentrations of the analytes in liquid environmental matrices (influent, effluent, river 
upstream and river downstream) during the monitoring week in WWTP E.  
 
 Ciprofloxacin 
 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 420.5 126.6 130.5 19.1 
Tues 479.5 154.0 123.0 19.8 
Wed 635.5 120.9 133.5 40.3 
Thu 394.5 77.1 142.0 56.6 
Fri 257.5 84.1 115.5 2.1 
Sat 389.0 162.6 217.5 14.8 
Sun 408.5 16.3 153.0 4.2 
 
 Desethylene-ciprofloxacin 
 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 334.1 58.4 82.1 6.8 
Tues 368.4 250.3 80.0 1.4 
Wed 373.8 18.6 74.6 4.4 
Thu 171.9 19.1 73.5 10.1 
Fri 171.6 47.7 72.3 1.4 
Sat 221.3 138.0 79.9 9.3 














 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 104.0 50.9 33.5 4.9 
Tues 150.0  32.0 9.9 
Wed 67.5 23.3 35.0 12.7 
Thu 65.0 15.6 37.5 14.8 
Fri 57.0 1.4 28.0 5.7 
Sat 80.0 39.6 64.5 0.7 









 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 287.0 116.0 90.5 19.1 
Tues 450.0  91.5 10.6 
Wed 224.0 99.0 78.0 11.3 
Thu 284.5 96.9 100.0 36.8 
Fri 158.5 6.4 79.5 7.8 
Sat 253.5 142.1 166.5 6.4 










































 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 4.5 2.1 2.5 0.7 
Tues 7.0 n.a. 3.0 0.0 
Wed 8.0 1.4 3.5 0.7 
Thu 5.5 0.7 2.5 0.7 
Fri 4.5 0.7 2.0 0.0 
Sat 4.0 1.4 3.5 0.7 















 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 26.0 11.3 3.0 0.0 
Tues 41.0 26.9 3.5 0.7 
Wed 31.5 19.1 4.5 0.7 
Thu 18.0 9.9 3.5 0.7 
Fri 14.0 0.0 3.0 0.0 
Sat 13.5 12.0 3.5 0.7 


















 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 















 Nalidixic acid 
 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 15.5 2.1 10.0 1.4 
Tues 44.5 16.3 8.5 2.1 
Wed 42.0 11.3 7.5 2.1 
Thurs 26.0 7.1 11.5 4.9 
Fri 27.5 17.7 14.5 0.7 
Sat 40.0 7.1 25.0 1.4 
Sun 34.5 2.1 11.5 0.7 
 
 Norfloxacin 
 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon 673.0 n.a. 183.5 37.5 
Tues  n.d.  -  164.0 4.2 
Wed 933.5 416.5 230.5 113.8 
Thurs 186.0 n.a.  150.5 37.5 
Fri  n.d.  -  170.5 21.9 
Sat 436.0 264.5 251.5 16.3 












 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - 6.5 0.7 
Tues 31.0 n.a. 6.0 0.0 
Wed n.d.  - 21.0 0.0 
Thu n.d.  - 8.0 2.8 
Fri n.d.  - 6.5 0.7 
Sat n.d.  - 16.0 1.4 








 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 





 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 

















 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 















 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - <MQL  - 
Wed n.d.  - <MQL  - 
Thu <MQL  - <MQL  - 
Fri n.d.  - <MQL  - 
Sat n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - <MQL  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 












  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 









  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - <MQL  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - <MQL  - 
Sat n.d.  - <MQL  - 





































Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 









Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 












 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 









 Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thu n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 





 Influent Effluent 
  Conc. (ng/L) SD Conc. (ng/L) SD 
Mon n.d.  - n.d.  - 
Tues n.d.  - n.d.  - 
Wed n.d.  - n.d.  - 
Thurs n.d.  - n.d.  - 
Fri n.d.  - n.d.  - 
Sat n.d.  - n.d.  - 




Table S13 Concentrations of qnrS gene in influent and effluent wastewater during the monitoring 
week in all the sites. 
 
qnrS 
Sample Copies/microliter CI Copies/microliter 
Town B influent Thursday 0.502 0.209 -- 1.205 
Town B influent Sunday 0.181 4.52E-2 -- 0.723 
Town B effluent Thursday 0.460 0.191 -- 1.105 
Town B effluent Sunday 7.61E-02 1.07E-2 -- 0.54 
Town D influent Thursday  0.761 0.396 -- 1.462 
Town D influent Thursday  0.658 0.314 -- 1.38 
Town D influent Sunday  1.994 1.347 -- 2.951 
Town D influent Sunday 2.076 1.367 -- 3.152 
Town D effluent Thursday 0.394 0.148 -- 1.049 
Town D effluent Sunday 1.018 0.382 -- 2.71 
Town A influent Friday 8.51E-02 1.20E-2 -- 0.604 
Town A influent Sunday 1.915 1.154 -- 3.176 
Town A effluent Friday 1.229 0.728 -- 2.076 
Town A effluent Sunday 1.748 1.14 -- 2.681 
City E SPM day 2 Thursday 20.229 17.635 -- 23.205 
City E SPM day 5 Sunday 35.502 32.237 -- 39.098 
City E influent day 1 Wednesday  0.951 0.527 -- 1.718 
City E influent day 1 Wednesday  1.286 0.775 -- 2.132 
City E influent day 2 Thursday 0.983 0.529 -- 1.827 
City E influent day 2 Thursday 0.681 0.325 -- 1.429 
City E influent day 3 Friday 0.424 0.177 -- 1.019 
City E influent day 3 Friday  0.406 0.169 -- 0.975 
City E  influent day 4 Saturday  0.628 0.3 -- 1.318 
City E influent day 4 Saturday  0.225 7.25E-2 -- 0.697 
City E influent day 5 Sunday  0.0761 1.07E-2 -- 0.54 
City E influent day 5 Sunday  0.550 0.262 -- 1.154 
City E influent day 6 Monday  1.742 1.136 -- 2.671 
City E influent day 6 Monday  0.791 0.412 -- 1.52 
City E influent day 7 Tuesday  1.158 0.672 -- 1.994 
City E influent day 7 Tuesday 0.937 0.519 -- 1.693 
City E effluent day 2 Thursday 0.498 0.224 -- 1.108 
City E effluent day 3 Friday 0.808 0.404 -- 1.616 
City E effluent day 4 Saturday 0.703 0.292 -- 1.688 
City E effluent day 5 Sunday 1.415 0.853 -- 2.348 
City E effluent day 6 Monday 4.184 3.18 -- 5.506 
City E effluent day 7 Tuesday 1.833 1.183 -- 2.841 
City C influent Thursday  0.614 0.293 -- 1.288 
City C influent Thursday 0.653 0.293 -- 1.454 
City C influent Sunday  1.559 0.995 -- 2.444 
City C influent Sunday  1.706 1.134 -- 2.567 
City C effluent Thursday  0.444 0.185 -- 1.068 
City C effluent Thursday 1.167 0.663 -- 2.055 
City C effluent Sunday 0.188 0.110 – 0.234 




Table S14 Concentrations of the analytes in suspended particulate matter from influent wastewater 
during the monitoring week in WWTP A.  
  
Concentration ± SD (ng/g)  
Monday Tuesday Wednesda
y 
Thursday Friday Saturday Sunday 
Ciprofloxacin 98.3 ± 31.4 55.9 ± 6.2 99.3 ± 7.4 45.8 ± 5.2 73.0 ± 10.0 58.5 ± 
10.7 
280.0 ± 57.3 
S-(-)-Ofloxacin 99.0 ± 18.8 58.9 ± 3.0 79.7 ± 12.9 74.3 ± 7.3 83.9 ± 6.5 140.0 ± 
3.2 
122.1 ± 32.3 
R-(+)-Ofloxacin 6.4 ± 2.8 17.3 ± 2.8 13.0 ± 5.8 7.5 ± 2.7 8.5 ± 1.8 4.2 ± 3.2 5.7 ± 2.9 




- 68.8 ± 
25.2 
- - - 
Nalidixic acid 1.4 ± 0.4 0.5 ± 0.2 0.8 ± 0.5 0.3 ± 0.1 0.2 ± 0.0 0.5 ± 0.2 0.6 ± 0.1 
R,R-Moxifloxacin - - - - - - - 
S,S-Moxifloxacin - - - - - - - 
Moxifloxacin-N-sulphate - - - - - - - 
S-(-)-Ofloxacin-N-oxide - - - - - - - 
R-(+)-Ofloxacin-N-oxide - - - - - - - 
S-(-)-Desmethyl-Ofloxacin - - - - - - - 
R-(+)-Desmethyl-
Ofloxacin 
- - - - - - - 
Desethylene-ciprofloxacin 27.0 ± 1.7 16.6 ± 1.8 14.8 ± 0.6 13.8 ± 1.0 16.2 ± 0.9 17.5 ± 0.8 16.8 ± 0.5 
E1-Flumequine 3.9 ± 1.0 1.2 ± 0.8 1.9 ± 0.5 0.9 ± 0.1 0.9 ± 0.8 2.0 ± 0.3 3.3 ± 0.2 
E2-Flumequine 1.7 ± 0.5  0.2 ± 0.2 0.4 ± 0.4 0.3 ± 0.1 0.5 ± 0.1 0.4 ± 0.4 0.6 ± 0.5 
E1-Prulifloxacin - - - - - - - 
E2-Prulifloxacin - - - - - - - 
Besifloxacin - - - - - - - 
Nadifloxacin-E1 - - - - - - - 
Nadifloxacin-E2 - - - - - - - 
Lomefloxacin - - - - - - - 
Ulifloxacin-E1 - - - - - - - 







Table S15 Concentrations of the analytes in suspended particulate matter from influent wastewater 
during the monitoring week in WWTP B.  
  
Concentration ± SD (ng/g)  
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Ciprofloxacin 4.5 ± 0.4 5.7 ± 0.3 6.7 ± 0.6 5.3 ± 0.5 4.9 ± 0.4 4.7 ± 0.8 5.7 ± 0.6 
























Norfloxacin 38.9 ± 9.1 73.1 ± 10.9 116.5 ± 
22.3 
61.0 ± 4.8 75.7 ± 9.5 80.7 ± 20.1 57.1 ± 7.7 
Nalidixic acid <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
R,R-Moxifloxacin - - - - - - - 
S,S-Moxifloxacin - - - - - - - 
Moxifloxacin-N-sulphate - - - - - - - 
S-(-)-Ofloxacin-N-oxide - - - - - - - 
R-(+)-Ofloxacin-N-oxide - - - - - - - 
S-(-)-Desmethyl-
Ofloxacin 
- - - - - - - 
R-(+)-Desmethyl-
Ofloxacin 
- - - - - - - 
Desethylene-
ciprofloxacin 
19.6 ± 0.3 24.8 ± 2.0 24.0 ± 3.3 19.5 ± 2.3 19.7 ± 0.8 17.6 ± 2.5 19.4 ± 1.3 
E1-Flumequine - - <MQL - <MQL - - 
E2-Flumequine <MQL - <MQL - - <MQL <MQL 
E1-Prulifloxacin - - - - - - - 
E2-Prulifloxacin - - - - - - - 
Besifloxacin - - - - - - - 
Nadifloxacin-E1 - - - - - - - 
Nadifloxacin-E2 - - - - - - - 
Lomefloxacin - - - - - - - 
Ulifloxacin-E1 - - - - - - - 





Table S16 Concentrations of the analytes in suspended particulate matter from influent wastewater 
during the monitoring week in WWTP C.  
  
Concentration ± SD (ng/g)  
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Ciprofloxacin 116.2 ± 11.6 74 ± 10.33 170.62 ± 
39.7 
80 ± 2.68 53.8 ± 10.8 104.1 ± 29.3 98.89 ± 
12.86 
S-(-)-Ofloxacin 109.63 ± 
13.77 












R-(+)-Ofloxacin 32.43 ± 4.48 18.22 ± 
3.20 




41.40 ± 1.31 44.72 ± 
11.92 
Norfloxacin - - - - - - - 
Nalidixic acid - - - - - - - 
R,R-Moxifloxacin - - - - - - - 
S,S-Moxifloxacin - - - - - - - 
Moxifloxacin-N-
sulphate 
- - - - - - - 
S-(-)-Ofloxacin-N-
oxide 
- - - - - - - 
R-(+)-Ofloxacin-N-
oxide 
- - - - - - - 
S-(-)-Desmethyl-
Ofloxacin 
<MQL <MQL <MQL <MQL <MQL <MQL <MQL 
R-(+)-Desmethyl-
Ofloxacin 











82.81 ± 3.58 131.07 ± 
32.97 
E1-Flumequine 2.00 ± 0.5 2.40  ± 
0.58 
3.45 ± 1.1 1.20  ± 
0.43 
1.53 ± 0.42 1.35 ± 0.41 1.45 ± 0.34 
E2-Flumequine 0.65 ± 0.41 0.80 ± 0.16 1.60 ± 0.99 0.35 ± 0.1 0.47 ± 0.19 0.65 ± 0.3 0.55 ± 0.19 
E1-Prulifloxacin - - - - - - - 
E2-Prulifloxacin - - - - - - - 
Besifloxacin - - - - - - - 
Nadifloxacin-E1 - - - - - - - 
Nadifloxacin-E2 - - - - - - - 
Lomefloxacin - - - - - - - 
Ulifloxacin-E1 - - - - - - - 





Table S17 Concentrations of the analytes in suspended particulate matter from influent wastewater 
during the monitoring week in WWTP D.  
  
Concentration ± SD (ng/g)  
Monday Tuesday Wednesday Thursday Friday Saturday Sunday 
Ciprofloxacin 397.1 ± 282.9 126.4 ± 42.6 236.7 ± 14.2 92.1 ± 31.8 372.6 ± 258.3 87.2 ± 15.3 130.6 ± 58.9 
S-(-)-Ofloxacin 112.3 ± 55.7 305.1 ± 202.2 112.0 ± 55.1 141.4 ± 81.4 134.6 ± 70.5 48.0 ± 1.7 56.8 ± 6.8 
R-(+)-Ofloxacin 69.4 ± 16.1 278.6 ± 202.9 92.4 ± 53.1 56.6 ± 14.5 118.4 ± 80.1 25.6 ± 6.5 41.2 ± 5.0 
Norfloxacin - - - 100.1 ± 36.8 299.9 ± 12.3 173.9 ± 60.0 - 
Nalidixic acid - - - - - - - 
R,R-Moxifloxacin - - - - - - - 
S,S-Moxifloxacin - - - - - 61.4 ± 3.7 - 
Moxifloxacin-N-sulphate - - - - - - - 
S-(-)-Ofloxacin-N-oxide - - - - - - - 
R-(+)-Ofloxacin-N-oxide - - - - - - - 
S-(-)-Desmethyl-Ofloxacin - - - - - - - 
R-(+)-Desmethyl-Ofloxacin - - - - - - - 
Desethylene-ciprofloxacin 201.4 ± 7.5 71.1 ± 19.8 54.6 ± 8.5 79.4 ± 24.2 58.1 ± 12.9 159.5 ± 31.2 63.0 ± 
28.5 
E1-Flumequine 1.5 ± 0.7 1.4 ± 0.5 2.0 ± 0.6 1.8 ± 0.8 2.2 ± 0.6 3.0 ± 0.2 2.3 ± 1.0 
E2-Flumequine 0.5 ± 0.1  0.5 ± 0.4 <MQL 0.4 ± 0.3 0.4 ± 0.1 0.7 ± 0.1 1.1 ± 2.2 
E1-Prulifloxacin - - - - - - - 
E2-Prulifloxacin - - - - - - - 
Besifloxacin - - - - - - - 
Nadifloxacin-E1 - - - - - - - 
Nadifloxacin-E2 - - - - - - - 
Lomefloxacin - - - - - - - 
Ulifloxacin-E1 - - - - - - - 





Table S18 Concentrations of the analytes in suspended particulate matter from influent wastewater 
during the monitoring week in WWTP E.  
  
Concentration ± SD (ng/g)  
Monday Tuesday Wednesda
y 
Thursday Friday Saturday Sunday 




102.4 ± 36.9 












208.7 ± 32.4 
R-(+)-Ofloxacin 79.0 ± 8.6 76.8 ± 15.0 60.7 ± 4.5 76.4 ± 23.4 63.5 ± 11.1 75.3 ± 12.6 78.9 ± 5.3 
Norfloxacin - 57.8 ± 28.0 40.6 ± 9.4 63.5 ± 2.6 62.7 ± 1.7 - - 
Nalidixic acid 5.5 ± 2.5 4.1 ± 3.4 12.0 ± 5.0 11.0 ± 2.8 11.0 ± 4.6 7.0 ± 5.8 9.7 ± 3.6 
R,R-Moxifloxacin - - - - - - - 
S,S-Moxifloxacin - - - - - - - 
Moxifloxacin-N-sulphate - - - - - - - 
S-(-)-Ofloxacin-N-oxide - - - - <MQL <MQL <MQL 
R-(+)-Ofloxacin-N-oxide - <MQL <MQL <MQL <MQL <MQL <MQL 
S-(-)-Desmethyl-
Ofloxacin 
- - - - - - - 
R-(+)-Desmethyl-
Ofloxacin 
- - - - - - - 
Desethylene-
ciprofloxacin 
- - - - - - - 
E1-Flumequine 3.4 ± 1.5 6.9 ± 1.8 5.6 ± 2.7 2.4 ± 0.8 1.3 ± 0.6 2.6 ± 0.6 1.9 ± 0.4 
E2-Flumequine 1.0 ± 0.3  1.1 ± 0.3 1.2 ± 0.4 0.7 ± 0.3 0.4 ± 0.1 0.6 ± 0.3 0.4 ± 0.2 
E1-Prulifloxacin - - - - - - - 
E2-Prulifloxacin - - - - - - - 
Besifloxacin - - - - - - - 
Nadifloxacin-E1 <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
Nadifloxacin-E2 <MQL <MQL <MQL <MQL <MQL <MQL <MQL 
Lomefloxacin - - - - - - - 
Ulifloxacin-E1 - - - - - - - 
Ulifloxacin-E2 - - - - - - - 
 
 
Table S19 Ratio between ciprofloxacin and its metabolite in all the sites. 
 
RATIO Town A Town B City C Town D City   E 
Monday   1.1 2.2 5.9 1.3 
Tuesday 9.5 1.5 3.3 5.5 1.3 
Wednesday 9.0 3.7   4.5 1.7 
Thursday 5.0 2.5 6.6 2.2 2.3 
Friday 5.8 3.8 9.1 2.5 1.5 
Saturday 5.5 3.0 3.9 2.5 1.8 
Sunday 5.6 3.4 3.3 3.9 1.2 
AV 6.7 2.7 4.7 3.9 1.6 
SD 2.0 1.1 2.6 1.5 0.4 
 
